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BACKGROUND: Cutis laxa (CL) is a group of disorders characterized by loose, inelastic, and 
redundant skin. The different types of CL are distinguished by clinical features, inheritance, and 
molecular findings.  The objective of this study was to characterize the pulmonary phenotype of 
the different types of CL based on age of onset (congenital, acquired/late-onset, or unknown) and 
mutational status.  The first aim of this study was to collect clinical data to better define the 
pulmonary involvement in cutis laxa.  The second aim was to determine if heterozygous carriers 
of recessive types of cutis laxa are susceptible to chronic lung disease.  METHODS: Clinical 
questionnaires, medical histories, and pulmonary function tests (PFTs) were used to collect 
clinical data on patients with a confirmed or suspected diagnosis of CL and unaffected first-
degree relatives with a known mutation (carriers).  The clinical data was then compared between 
the groups categorized by age of onset and between those with known mutations (mutational 
status).  RESULTS: The clinical questionnaires and medical histories of 83 CL patients with 8 
acquired/late-onset, 52 congenital, and 23 of unknown etiology and 5 carriers were analyzed.  In 
addition, mutations have been identified in 27 of the 83 patients in ELN, FBLN4, FBLN5, 
ATP6V0A2, or LTBP4, and the 5 carriers had mutations in either FBLN4 or LTBP4.  The most 
common respiratory responses amongst the patients included pneumonia (24.1%), tachypnea 
(15.7%), and emphysema (12.0%).  The only statistically significant finding was dyspnea in 
acquired/late-onset patients.  Of those with a known mutation, 15 reported pulmonary 
involvement, with 10 of these individuals having at least one LTBP4 mutation.  For the 13 PFTs 
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collected, the 10 CL patients ranged from normal lung function to very severe obstruction, and 3 
carriers were deemed to have normal function.  An important new finding was the presence of 
pulmonary obstructive disease in those with ATP6V0A2 mutations.  CONCLUSION: These 
results demonstrate a high prevalence and significant heterogeneity of pulmonary complications 
in CL.  Further research is needed to determine any correlation between specific pulmonary 
findings and genotypes. PUBLIC HEALTH SIGNIFICANCE: Chronic lung disease is a 
common cause of morbidity in the general population. Uncovering the genetic basis of chronic 
lung disease in inherited syndromes has the potential to identify key molecular targets for 
improved diagnosis and treatment of common respiratory ailments. 
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1.0  INTRODUCTION 
Cutis laxa (CL) is a phenotypically and genetically heterogeneous group of conditions 
characterized by the presence of loose, lax, inelastic, and redundant skin.  The different types of 
CL are classified by clinical presentation, inheritance, and molecular findings.  To date at least 
nine different types of CL have been classified.  These types demonstrate autosomal dominant 
and recessive inheritance, X-linked inheritance, and acquired onset.  Mutations in several genes 
are known to cause cutis laxa: copper transporting adenosine triphosphatase (ATP7A), elastin 
(ELN), fibulin-4 (FBLN4), fibulin-5 (FBLN5), the A2 subunit of the vacuolar-type H+ -ATPase 
(ATP6V0A2), pyroline-5-carboxylate reductase 1 (PYCR1), latent transforming growth factor-
beta-binding protein 4 (LTBP4), and a guanine nucleotide exchange factor (GEF) for RAB5 
(RIN2).  The majority of these proteins are known components of or are involved in the 
formation of elastic fibers.  Of the clinical findings there is an overlap between the different 
types with common features including cutis laxa, joint laxity, hernias, bladder and/or intestinal 
diverticulae, and developmental or growth delays.  Other significant systemic involvement 
affects the cardiovascular and pulmonary systems.  The most common cardiovascular findings 
include aortic dilation and aneurysm, vascular tortuosity, and stenosis.  The most common 
pulmonary features include obstructive lung disease, emphysema, and recurrent respiratory 
infections.   The cardiovascular and pulmonary complications cause significant morbidity for 
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cutis laxa patients.  The objective of this study is to better characterize the pulmonary phenotype 
of the different types of CL based on age of onset and mutational status. 
3 
2.0  BACKGROUND 
2.1 TYPES OF CUTIS LAXA 
2.1.1 Occipital Horn Syndrome (OHS) 
X-linked Cutis Laxa (XCL) 
Previously known as Ehlers-Danlos Syndrome Type IX 
 
OHS is an X-linked type of cutis laxa caused by mutations in the gene ATP7A.  This type is 
characterized by the presence of skeletal anomalies that include occipital exostoses, skin laxity, 
joint laxity, hernias, bladder diverticulae, vascular tortuosity, dysautonomia, and low-normal 
intelligence (Lazoff et al 1975, Byers et al 1980, Kaler et al 1994). The clinical features of OHS 
are related to a decrease in the activity of the copper transporting adenosine triphosphatase 
(ATP7A).  As a result there is a decrease in intestinal absorption of copper, leading to low serum 
copper and ceruloplasmin, and accumulation of copper in fibroblasts (Das et al 1995). 
Mutations in ATP7A are also known to cause Menkes disease (MD) (Mercer et al 1993, 
Vulpe et al 1993, Chelly et al 1993).  MD is a lethal disorder characterized by neurodegeneration 
and “kinky” hair.  Those affected typically present with failure to thrive and developmental 
delay.  There can be vascular, urinary, skeletal, and muscular involvement.  A common skin 
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feature is seborrheic dermatitis. Mutations typically result in complete loss of function of 
ATP7A, thus causing a more severe phenotype. 
Kaler et al (1994) demonstrated that those with OHS, or milder Menkes disease variants, 
have residual ATP7A expression.  Splicing mutations in ATP7A have been found in a majority of 
OHS patients (Kaler et al 1994, Das et al 1995, Ronce et al 1997, Qi & Byers 1998).  Other 
mutations reported include frameshift and missense (Tang et al 2006, Dagenais et al 2001, 
Levinson et al 1996).  Several of these groups showed low levels of normal transcripts, and 
Moller et al (2000) & Gu et al (2001) found normal transcript levels of 2-5%.  In these cases the 
presence of low levels of normal transcript or low protein function explains the milder features 
compared to Menkes disease.  
2.1.2 Autosomal Dominant Cutis Laxa (ADCL) 
ELN-Related Cutis Laxa 
 
In 1972, Beighton provided a review of the autosomal dominant and recessive forms of cutis 
laxa.  The review noted that skin laxity was the only finding in the majority of reported cases of 
dominant cutis laxa.  Other health complications noted included pulmonary or cardiovascular 
features.   Damkier et al (1991) reported additional systemic involvement in a family with three 
affected individuals (in five generations) with gastrointestinal diverticulae, hernias, genital 
prolapse, and muscle weakness.  No pulmonary or cardiovascular findings were reported in this 
family. Since these publications a number of cases with variable systemic involvement have been 
described. 
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Mutations in the elastin gene (ELN) have been shown to cause autosomal dominant CL 
(ADCL) (Tassabehji et al 1998).  Elastin is the main component of elastic fibers.  It is secreted 
from the cell as tropoelastin monomers that are cross-linked to form polymers by a lysyl oxidase 
enzyme (Narayanan et al 1977).  Elastin is thought to provide the elastic coil of the fiber 
(Partridge 1962).  The other components of elastic fibers are microfibrils.  Microfibrils are made 
up of fibrillins, latent transforming growth factor-beta-binding proteins (LTBPs) (Gibson et al 
1995), microfibril associated glycoproteins (MAGPs) (Gibson et al 1996), and fibulins (Timpl et 
al 2003).  Microfibrils are suggested to provide a scaffold, thus the shape, of the elastic fiber, and 
thought to position the tropoelastin monomers for cross-linking (Narayanan et al 1977).  The 
greatest level of expression of elastic fiber proteins are primarily during the prenatal and neonatal 
periods, after about 21 days postnatal levels decrease and remain at a stable low rate during 
adulthood (Marianai, Reed, Shapiro 2002). 
Tassabehji et al (1998) first detected a deletion in ELN in exon 32.  The patient had cutis 
laxa, a cardiac murmur, and right ventricular hypertrophy. Elastin fibers in the patient’s 
fibroblasts had abnormal structure and were present in low amounts.  As a result, Tassabehji et al 
proposed that mutant tropoelastin was incorporated into the elastic fibers, and the monomers 
were packed abnormally.  As a result, there was less elastic recoil due to a loose 
framework/abnormal architecture.  They suggested that this could explain the cutis laxa, hernias, 
and pulmonary stenoses seen in those affected, and that cutis laxa was due to a dominant 
negative effect. 
Abnormalities of the tropoelastin and the mature elastin have also been shown by Hu et al 
(2010) and Callewaert et al (2011).  Using mouse models, Hu et al (2010) demonstrated that 
incorporation of mutant elastin into elastic fibers was needed for the development of cutis laxa.  
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In these mice, the lung elastic recoil was reduced.  Callewaert et al (2011) showed poor 
integration of mutant tropoelastin into elastin fibers is a result of increased aggregation of the 
mutant tropoelastin and decreased binding to microfibrils.  Similar findings have been shown in 
other types of cutis laxa (Hu et al 2006, Hucthagowder et al 2009). 
The majority of mutations identified in ELN result in stable transcripts with a disruption 
of the C-terminus (Callewaert et al 2011, Urban et al 2005, Rodriquez-Revenga et al 2004, 
Zhang et al 1999). Most mutations in ADCL are short deletions or insertions within the last 4 
exons of ELN (exons 30-34) causing a reading frame shift which replaces the C-terminus of 
tropoelastin with a missense peptide sequence. (Zhang et al 1999, Szabo et al 2006, Callewaert et 
al 2011, Rodriquez-Revenga et al 2004). In addition, a partial tandem duplication (Urban et al 
2005) and a splicing mutation in exon 25 of ELN (Graul-Neumann et al 2008) were also reported 
in ADCL.  In addition, a dominant mutation was found in the gene FBLN5 (Markova et al 2003). 
As FBLN5 mutations generally cause ARCL1, this finding blurs the distinction between genetics 
of ADCL and autosomal recessive CL (ARCL). 
The clinical features of ADCL individuals with ELN mutations include pulmonary and 
cardiovascular manifestations.  Cardiovascular involvement comprises redundant mitral and 
tricuspid valves, right ventricular hypertrophy (Zhang et al 1999), mitral valve stenosis and 
regurgitation, regurgitation of the aortic valve (Rodriquez-Revenga et al 2004), and aortic 
dilation, aneurysm, dissection and rupture (Callewaert et al 2011, Szabo et al 2006).  Pulmonary 
involvement includes reduced expiratory flow and dyspnea (Zhang et al 1999), emphysema 
(Graul-Neumann et al 2008, Urban et al 2005, Rodriquez-Revenga et al 2004), obstructive 
pulmonary disease and recurrent respiratory infections (Callewaert et al 2011).  Characteristic 
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facial features include coarse facies, long philtrum, hooked nose, and large dysplastic ears 
(Callewaert et al 2011). 
Of these ADCL cases, a demonstrative example is the tandem duplication in ELN 
identified in a mother-daughter pair (Urban et al 2005) previously described by Corbett et al 
(1994).  Both had cutis laxa and pulmonary complications.  Due to severe COPD, the mother 
received a double lung transplant.  Prior to lung transplant she had frequent lung infections and 
was diagnosed with bronchiectasis, and emphysema was confirmed at age 36 years.  She also 
had an inguinal hernia.  Her daughter was found to have emphysema based on lung function 
tests.  Of relevance both had a history of smoking and were M/Z heterozygotes for alpha-1-
antitrypsin.  However, only a minority of such individuals will develop emphysema (Dahl et al 
2002), typically with onset after the fourth decade of life.  Evidence of emphysema was present 
in the second to third decades of life in these patients. 
The cases described by Szabo et al (2006) suggest that ELN mutations can involve 
cardiac abnormalities.  These cases were from two families.  In family 1 all affected members 
had either aortic dilatation or severe aneurysm or dissection, only two members had cutis laxa, 
and two members had inguinal hernias.  Family 2 had one affected individual with cutis laxa and 
aortic dilatation.  This group of researchers demonstrated that ELN mutations that are associated 
with cutis laxa may also cause aortic disease. 
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2.1.3 Autosomal Recessive Cutis Laxa Type 1 (ARCL1) 
FBLN4 (EFEMP2)-Related Cutis Laxa 
FBLN5-Related Cutis Laxa 
 
Autosomal recessive CL type 1 (ARCL1) is caused by mutations in the FBLN4 (EFEMP2) and 
FBLN5 genes.  Those with FBLN4 mutations were found to have generalized cutis laxa, 
emphysema, respiratory infections, arterial tortuosity and aortic dilation or aneurysm, hernias, 
joint laxity, and arachnodactyly, and bone fragility.  Those with FBLN5 mutations were found to 
have cutis laxa, emphysema, respiratory infections, supravalvular aortic stenosis (SVAS), and 
hernias.  To date three cases have been reported with FBLN4 mutations, and eight cases have 
been reported with FBLN5 mutations.   
Fibulins (FBLNs) are a family of proteins associated with elastic fiber formation.  To 
date seven FBLNs have been identified, and each has calcium-binding EGF-like domains and a 
conserved C-terminal domain (Argraves et al 2003, Timpl et al 2003).  Fibulins are involved in 
organogenesis and expressed in a variety of systems, primarily in blood vessels (Argraves et al 
2003).   
The gene for the EGF-containing fibulin-like extracellular matrix protein 2 (EFEMP2), is 
also known as fibulin 4 (FBLN4). Fibulin 4 is primarily expressed in the large veins and arteries 
and some capillaries (Argraves et al 2003).  Mouse models have shown that fibulin 4 directly 
interacts with tropoelastin and may be involved in its deposition onto fibrillin microfibrils 
(McLaughlin et al 2006).  In addition, loss of fibulin 4 may affect the cross-linking of 
tropoelastin monomers.  The primary findings in these mouse models are vascular anomalies, 
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which include arterial tortuosity, dilation, and aneurysms (Horiguchi et al 2009, McLaughlin et 
al 2006). 
Fibulin-5 is encoded by the FBLN5 gene, also called DANCE (developmental arteries and 
neural crest EGF-like).  Fibulin 5 has been shown to be expressed in the arterial vasculature 
(Argraves et al 2003). Mouse models have demonstrated that fibulin 5 binds to tropoelastin, 
directly interacts with elastic fibers, and is involved in the maturation of the elastic fiber 
(Nakamura et al 2002, Yanagisawa et al 2002). Fibulin 5 also promotes adhesion of elastic fibers 
to cells (Nakamura et al 1999).  Fibulin-5 deficient mice present with cutis laxa (loose skin), 
arterial and aortic tortuosity, and emphysema (Nakamura et al 2002). 
2.1.3.1 Mutations in FBLN4 
Hucthagowder et al (2006) reported the first case of fibulin-4 (FBLN4) related cutis laxa.  The 
patient was born with multiple fractures, and at 9 months was diagnosed with generalized cutis 
laxa, transparent skin, hypotonia, emphysema, arterial tortuosity, inguinal and diaphragmatic 
hernias, joint laxity, and pectus excavatum.  At 2 years of age the patient was diagnosed with 
aortic root aneurysm.  Mutational analysis revealed homozygosity for a FBLN4 mutation 
(c.169G>A, p.E57K). Evaluation of fibroblasts revealed reduced levels of FBLN4 in the 
extracellular matrix and underdeveloped elastic fibers.  These results demonstrated that the 
mutation E57K severely impaired the secretion of the FBLN4. 
Dasouki et al (2007) reported a second case.  The patient was noted to have long hands, 
mild generalized skin laxity, pulmonary hypertension, dilation of the ascending aorta and 
dissection of the wall of the main braches of the pulmonary arteries, dilated great vessels, 
tortuous abdominal aorta, enlarged right ventricle and right atrium, multiple episodes of 
bradycardia, and development of pneumonia.  The patient passed away at 27 days of age.  
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Mutational analysis revealed compound heterozygous mutations in FBLN4 (c.835C>T, 
p.R279C; c.1070_1073dupCCGC).  Histological evaluation revealed similar findings as 
Hucthagowder et al (2006). 
Hoyer et al (2009) reported a third case of FBLN4 related cutis laxa.  The patient was 
noted to have cutis laxa, arachnodactyly, medial rotation of the feet, spina bifida, joint laxity, 
facial dysmorphism, and microcephaly.  Autopsy revealed hypoplastic diaphragm, collapsed 
lungs, emphysematous lung changes, and vascular tortuosity.  Mutational analysis revealed 
homozygosity for a FBLN4 mutation (c.800G>A, p.C267Y).  Histological evaluation revealed 
fragmentation of elastic fibers. 
Mutations in FBLN4 have also been found in three patients with arterial tortuosity, 
aneurysms, and/or stenosis (Renard et al 2010).   Of these three patients none had cutis laxa, and 
one had velvety skin but normal scarring.  As Renard et al mentions, these patients have a 
clinical overlap with Loeys-Dietz syndrome caused by mutations in TGFBR1 and TGFBR2, and 
arterial tortuosity syndrome caused by mutations in SLC2A10 (GLUT10).  Therefore, screening 
of FBLN4 should be considered in cases with these types of features when mutations are not 
found in TGFBR1, TGFBR2, or SLC2A10. 
2.1.3.2 Mutations in FBLN5 
A large consanguineous family was identified by Loeys et al (2002) and was found to be 
homozygous for a mutation in FBLN5 (c.998T>C, p.S227P).  Within the family, four individuals 
were noted to have cutis laxa.  The proband was diagnosed with supravalvular aortic stenosis and 
emphysema, and had recurrent lower respiratory tract infections.  Three siblings from a separate 
branch of the family were all noted to have cutis laxa, emphysema, and recurrent respiratory 
infections.  In addition, one had pulmonary hypertension due to peripheral pulmonary artery 
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hypoplasia, and another had bladder diverticulae.  All three passed away between the ages of 6 
months to 22 years due to cardiorespiratory failure. 
Elahi et al (2006) reported a consanguineous family with two affected children.  One 
sibling was reported to have cutis laxa, umbilical hernia, emphysema, supravalvular aortic 
stenosis, and a hoarse voice.  Evaluation of fibroblasts revealed abnormal and reduced elastic 
fibers.  The patient passed away at the age of 14 years.  The second sibling was reported to have 
similar skin findings, and passed away at the age of 2 due to pulmonary infections.  Mutational 
analysis revealed homozygosity for a FBLN5 mutation (679T>C, p.S227P).   
Claus et al (2008) reported a consanguineous family with two affected children.  The first 
sibling was noted to have cutis laxa, facial dysmorphism, bilateral inguinal hernias, large and 
delayed closure of the anterior fontanel, dilated right ventricle, and joint laxity.  The second 
sibling was noted to have cutis laxa, facial dysmorphism, bilateral inguinal hernias, 
kyphoscoliosis, small ostium secundum, delayed bone maturation, and severe emphysema.  
Fibroblasts from both patients were analyzed and revealed absence of elastic fibers.  Mutational 
analysis revealed homozygosity for a FBLN5 mutation (649T>C, p.C217R). 
Hu et al (2006) analyzed the functional affects of two reported FBLN5 mutations, 
p.S227P and p.C217R, on fibulin-5 and elastin.  They showed that the mutation S227P causes 
reduced synthesis and secretion of fibulin-5.  In addition, they demonstrated that both mutations 
result in fibulin-5 mutant proteins that cannot interact with elastin fibers, therefore showing that 
they are null mutations with respect to elastin fiber formation.   
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2.1.4 Autosomal Recessive Cutis Laxa Type 2 (ARCL2) 
ARCL type 2 (ARCL2) is characterized by the presence of a large fontanel with delayed closure, 
dysmorphic features, growth and developmental delays.  Of those affected, some may develop 
seizures and mental deterioration (Morava et al 2005, Kornak et al 2008).  Two types of ARCL2 
have been described in literature, ARCL2 Type A (ARCL2A) and ARCL2 Type B (ARCL2B).  
These types are distinguished by clinical features, glycosylation anomalies, and molecular 
genetic findings. 
2.1.4.1 Autosomal Recessive Cutis Laxa Type 2A 
ATP6V0A2-Related Cutis Laxa 
 
In a group of patients with ARCL2, Kornak et al (2008) analyzed the glycosylation of serum 
proteins.  The results of this analysis revealed a defect of N-glycosylation and O-glycosylation, 
consistent with a congenital disorder of glycosylation (CDG) type 2 pattern.  CDG is a class of 
disorders characterized by glycosylation defects at the level of the endoplasmic reticulum or 
Golgi apparatus (Freeze 2006). With these results, homozygosity mapping of 15 consanguineous 
families was pursued, and mutations in the gene ATP6V0A2 were found.  This gene encodes the 
A2 subunit of the vacuolar-type H+ -ATPase.  Kornak et al (2008) identified 10 different 
mutations among 12 families.  Hucthagowder et al (2009) identified 18 different mutations 
among17 patients. Some of the families in both studies were initially diagnosed with wrinkly 
skin syndrome (WSS) All of these mutations are predicted to result in a loss of function.  It is 
proposed that loss of function of ATP6V0A2 leads to elevated vesicle pH and premature 
aggregation of tropoelastin.  This then may impair tropoelastin secretory vesicle trafficking, 
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leading to accumulation within the cell (Hucthagowder et al 2009).  Fibroblasts from affected 
patients demonstrated this accumulation. 
ARCL2A is characterized by the presence of cutis laxa, large fontanels or delayed 
closure, microcephaly, eye anomalies including strabismus, myopia, and hypermetropia, joint 
laxity, and developmental delay, mental retardation (Hucthagowder et al 2009, Morava et al 
2008, Van Maldergem et al 2008).  Other relevant findings include partial pachygyria, and 
cardiac, urogenital, liver, and coagulation anomalies.  Several patients have been reported to 
develop seizures later in life (Morava et al 2008).  Of importance, growth delay was seen in low 
frequency among the reported patients, a previously reported characteristic finding of ARCL2. 
2.1.4.2 Autosomal Recessive Cutis Laxa Type 2B (ARCL2B), Geroderma Osteodysplastic 
(GO), & Wrinkly Skin Syndrome (WSS) 
Cutis Laxa with Global Developmental Delay (CLGDD) 
Cutis Laxa with Progeroid Features 
 
ARCL2B (previously called cutis laxa with global developmental delay) and GO are two 
conditions in which cutis laxa is primarily localized to the dorsum of the hands and feet.  In the 
literature there has been much debate over whether these two conditions represent the same 
condition or are indeed two distinct conditions.  In addition, the term wrinkly skin syndrome 
(WSS) has been used to describe individuals with both of these conditions, and as a separate 
condition. Even after the identification of the causative genes for ARCL2B and GO (PYCR1 and 
SCYL1BP1/GORAB respectively) by Guernsey et al (2009), Reversade et al (2009), and Hennies 
et al (2009), there is still discussion about the classification of these conditions. 
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GO is characterized by the presence of lax and wrinkled skin predominantly on the hands 
and feet, dysmorphic facial features including a broad, prominent forehead, mandibular 
prognathism, and large protruding ears.  Other findings include joint laxity, which results in hip 
dislocation in many cases, and some level of developmental delay. Common radiological 
features include osteoporosis, wormian bones, and multiple fractures (Al-Gazali et al 2001). 
WSS is characterized by the presence of wrinkled skin on the dorsum of the hands and 
feet and abdomen, increased palmar and plantar creases, prenatal and postnatal growth delays, 
and developmental delays (Al-Gazali et al 2001, Boente et al 1999).  Other noted features 
include musculoskeletal complications including joint laxity, hypotonia, microcephaly, and a 
prominent venous pattern on the chest. Due to the level of overlap, Zlotogora (1999) suggested 
that WSS and ARCL2B are the same syndrome before glycosylation and molecular genetic 
testing became available for distinguishing these patients.   
In 2001, Al-Gazali et al described five patients from two families diagnosed with 
overlapping features of GO and WSS.  Patients were described to have intrauterine growth 
retardation, growth and developmental delays, dysmorphic facial features, joint laxity, winged 
scapula, hip dislocation, wrinkly skin, prominent veins, prominent palmar/plantar creases, 
osteoporosis, and wormian bones.  Al-Gazali et al. as well as others (Hamamy et al. 2005) 
suggested that the conditions GO, WSS, and cutis laxa with developmental delay represent the 
same syndrome.  Differences between the three may represent the variability of the syndrome 
and lack of a full assessment when diagnosed.  For instance, individuals with WSS and cutis laxa 
do not typically have radiological evaluations to determine the presence of osteoporosis or 
wormian bones.   
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Rajab et al (2008) described 22 patients, eight with GO and 14 with WSS.  Based on 
clinical evaluations they disagreed with Al-Gazali et al (2001), and stated that GO and WSS are 
distinct syndromes.  This is due to the extent of wrinkling present, where GO skin wrinkling is 
localized to the hands and feet, and WSS skin wrinkling can be more generalized.  Rajab et al 
(2008) and Zlotogora (1999) suggested that there are no major clinical differences between WSS 
and ARCL2B (CLGDD). 
Nanda et al (2008) described three patients and reviewed the literature.  They suggested 
that not all cases of ARCL2B can be grouped with WSS.  Individuals with CL presenting with 
developmental delay have soft doughy skin with redundant folds, and those with WSS have thin, 
inelastic, and wrinkly skin primarily affecting the hands and feet. 
Genetics of ARCL2B 
In 2009, Guernsey et al described five patients with lax, wrinkled, inelastic skin, joint laxity, and 
facial dysmorphism.  The skin findings are prominent on the hands and feet, and the facial 
dysmorphism included microcephaly, and a broad, prominent forehead.  Two of the five had 
congenital hip dislocation.  All of the patients had some degree of prenatal and postnatal growth 
deficiency, and developmental delays.  No radiological evaluations were performed.  
Homozygosity analysis revealed a potentially pathogenic variant in the gene PYCR1 (c.797G>A, 
p.R226Q).  Further analysis demonstrated that this mutation leads to a loss of function of 
PYCR1.  They conclude that this loss of function is responsible for the phenotype seen in their 
patients. 
Reversade et al (2009) detected 15 mutations in PYCR1 in 35 affected individuals from 
22 families initially diagnosed as WSS, GO or DBS.  The generalized clinical features of these 
individuals included skin wrinkling primarily on the hands and feet, finger contractures, hernias, 
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osteopenia, and a triangular shaped face often with proganthism.  Variable degrees of mental 
retardation were reported in all but one case.  
PYCR1 encodes for the enzyme pyroline-5-carboxylate reductase 1.  Protein expression 
analysis in fibroblasts demonstrates that PYCR1 is a mitochondrial protein.  Mutations reported 
by Reversade et al were demonstrated to result in a loss of function leading to abnormal 
morphology of the mitochrondria and increased cell death. 
Genetics of GO 
Newman et al (2008) mapped GO to a 4 Mb locus on chromosome 1q24 in 10 individuals from 
five families.  Then, Hennies et al (2008) identified nine different mutations in the gene 
SCYL1BP1 (NTKLBP1/GORAB) in 13 families with a GO phenotype. GO was diagnosed based 
on a lack of large fontane with delayed closure, facial dysmorphism with downslanting palpebral 
fissures, generalized skin wrinkling, and mental retardation or neurodegenerative deterioration.  
SCY1BP1 encodes for SCY-like 1 binding protein 1, which is localized to the Golgi apparatus 
and is involved in vesicle transport.  Fibroblast evaluation demonstrated that these mutations had 
a loss-of-function effect. 
Al-Dosari & Alkuraya (2009) confirmed the findings of Hennies et al. Seven patients in 
four families were diagnosed with GO based on similar criteria as Hennies et al.  Homozygosity 
and genomic analysis revealed two mutations (c.226_227insA, p.Q76QfsX20; c.658G>C, 
p.A220P) in SCYL1BP1.  These mutations were proposed to be loss of function mutations. 
However, Yildirim et al (2010) identified PYCR1 mutations in four patients diagnosed 
with GO.  The diagnosis was based on the presence of wrinkled skin predominantly on the hands 
and feet, broad, prominent forehead, prognathism, and variable degrees of osteopenia and 
wormian bones.  Yildirim et al (2010) discusses that overall, the syndromes caused by mutations 
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in SCYL1BP1 (GO) and PYCR1 (ARCL2B) are clinically similar.  The major differences 
between the two syndromes is mental retardation in ARCL2B and more severe osteoporosis in 
GO. 
2.1.5 De Barsy Syndrome 
De Barsy syndrome was first described by de Barsy et al. in 1967 and since that time 28 
additional cases have been reported in literature.  Kivuva et al (2008) provided a review of all 
cases and described the prominent features of this syndrome.  The most common features include 
cutis laxa (97%), musculoskeletal complications (90%), mild to severe developmental delay 
(76%), dysmorphic facial features (up to 79%), hypotonia (72%), and corneal opacification 
(48%).  Muscoloskeletal complications included joint laxity, joint dislocations and/or 
contractures, clubbed foot, pectus excavatum, delayed bone age, and scoliosis.  Dysmorphic 
facial features included progeroid features, large, low-set ears, prominent forehead, large 
fontanels, thin lips or small mouth, and small nose.  Reversade et al (2009) have found mutations 
in PYCR1 in several families diagnosed with DBS, suggesting that this disease is allelic with 
ARCL2B. 
18 
2.1.6 Urban-Rifkin Davis Syndrome (URDS) 
Cutis laxa with severe pulmonary, gastrointestinal, and urinary abnormalities 
LTBP4-Related Cutis Laxa 
 
Urban et al (2009) reported a new type of autosomal recessive cutis laxa, called Urban-Rifkin-
Davis syndrome (URDS) based on four patients with generalized cutis laxa.  All had some 
degree of facial dysmorphism including long philtrum, flat midface, receding forehead, and 
microretrognathia.  Major complications were due to pulmonary, gastrointestinal, and urinary 
abnormalities.  Pulmonary complications included tachypnea or respiratory distress, emphysema, 
tracheomalacia, and diaphragmatic hernia.  Three of the four passed away due to respiratory 
failure.  Gastrointestinal and genitourinary complications included diverticulae, intestinal 
dilation or tortuosity, and umbilical and inguinal hernias.  Other findings included pulmonary 
artery stenosis, joint laxity, hypotonia, and postnatal growth delay.  The patients described by 
Urban et al were found to be either homozygous or compound heterozygous for mutations in 
LTBP4, which encodes latent transforming growth factor-beta-binding protein 4.   
There are four different types of latent transforming growth factor-beta-binding proteins 
(LTBPs).  These proteins vary in expression from wide to localized.  All four are involved in the 
regulation of transforming growth factor beta (TGF-beta), which is involved in the growth and 
differentiation of various cell types (Oklo & Hesketh 2000).  LTBP4 has been shown to be 
expressed in the heart and aorta, pancreas, small intestine, lung, liver, kidney, and muscular 
system (Giltay et al 1997, Saharinen et al 1998).  Urban et al (2009) demonstrated the first 
association of the LTBP4 gene with disease.  They identified five mutations in the gene.  Most of 
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the mutations (four out of five identified) reported were nonsense mutations leading to reduced 
amounts of LTBP4 in fibroblasts.  In addition, four of the five identified mutations were located 
in domains that are known to affect fibrillin and LTBP conformation.  Functional analysis 
demonstrated abnormal release and/or storage of TGF-beta, thus changing its availability in the 
extracellular matrix (ECM) and affecting its incorporation into the ECM.  Therefore, LTBP4 
deficiency, may lead to changes in the development of pulmonary, intestinal, and urinary 
systems where LTBP4 is primarily expressed in. 
2.1.7 Macrocephaly, Alopecia, Cutis Laxa and Scoliosis (MACS) Syndrome 
RIN2-Related Cutis Laxa 
 
Six patients, from two families, were described by Basel-Vanagaite et al (2009) and Syx et al 
(2010) to have macrocephaly, receding hairlines and sparse hair (alopecia), progressive facial 
coarsening and swelling, joint laxity, scoliosis, high-pitched voices, and cutis laxa.  The 
condition was mapped to chromosome 20p11.21-p11.23, and patients were found to be 
homozygous for a mutation in RIN2 (c.1731delC, p.I578SfsX4; c.1914_1915delGC, 
p.Glu638AspfsX9). RIN2 is a guanine nucleotide exchange factor (GEF) for RAB5, a protein 
involved in endocytosis (Saito et al 2002). Functional analysis demonstrated decreased mRNA 
and protein levels in fibroblasts of the patients.  In addition, deficiency of RIN2 was shown to be 
associated with a deficiency of fibulin-5 (FBLN5) and paucity of dermal microfibrils (Basel-
Vanagaite et al 2009), which are involved in elastin fiber formation.  Basal-Vanagaite et al 
proposed that the newly described condition be called MACS syndrome (macrocephaly, 
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alopecia, cutis laxa, and scoliosis).  Syx et al (2010) proposed that this condition be called RIN2 
syndrome. 
2.1.8 Acquired Cutis Laxa 
Acquired cutis laxa is a condition characterized by the presence of lax, redundant, and inelastic 
skin, which typically affects adults.  However, several isolated cases of children and adolescents 
have been reported (Lewis et al 2004).  The extent of skin involvement ranges from localized 
areas to generalized skin laxity.  In approximately half of cases, an inflammatory phase precedes 
the onset of skin laxity.  Other health complications associated with acquired cutis laxa include 
emphysema, cor pulmonale, aortic dilation and rupture, intestinal diverticulae, and inguinal and 
hiatal hernias (Lewis et al 2004, Hashimoto & Kanzaki 1975, Reed et al 1971).  These additional 
health complications are proposed to be caused by a high rate of systemic elastolysis (Koch & 
Williams 1985).   
The cause of acquired cutis laxa remains relatively unknown.  Conditions associated with 
acquired cutis laxa include multiple myeloma (Gupta & Helm 2002, Nikko et al 1996, McCarty 
et al 1996, Ting et al 1984, Cho & Maguire 1980, Scott et al 1976),  kidney disease (Tan et al 
2003, Tsuji et al 1987), lymphoma (Chartier et al 1997, Machet et al 1995), celiac disease 
(Garcia-Patos et al 1996), and rheumatoid arthritis (Rongioletti et al 2002), and radiation therapy 
(Koch & Williams 1985). In addition, several studies have examined the histopathology of 
acquired cutis laxa.  These studies have shown disarrangement of collagen fibers, fragmented, 
clumped and reduced elastic fibers, and absent or reduced amounts of oxytalanic fibers (de 
Almeida et al 2008, Bouloc et al 1999, Lebwohl et al 1994, Nanko et al 1979). 
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In 2006, Hu et al reported a patient with acquired cutis laxa who had missense mutations 
in ELN and FBLN5.  The patient developed cutis laxa after a Toxocara canis parasitic infection.  
Other health complications that developed included aortic root aneurysm and B-cell lymphoma.  
Mutational analysis revealed compound heterozygosity for ELN mutations (p.A55V; p.G773D) 
and heterzygosity for a FBLN5 mutation (p.G202R).  Functional analysis determined that the 
FBLN5 mutation G202R may increase FBLN5 binding potential with ELN, and that the ELN 
mutation G773D may be sufficient to cause cutis laxa.  Therefore, the FBLN5 mutation G202R 
may partially rescue the ELN mutation G773D.  At this time, no other similar cases have been 
reported. 
The case described by Hu et al raises an important question of whether the term 
“acquired” is appropriate for all later-onset cases of cutis laxa.  Therefore, for patients described 
in this paper with later onset CL will be classified as “Acquired/Late-Onset Cutis Laxa.”
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Table 1: Summary Table of CL Types. 
CL Type Gene Inheritance Clinical Features 
Occipital Horn Syndrome  
(OHS) 
ATP7A X-linked Cutis laxa, joint laxity, occipital exostoses, hernias, vascular tortuosity, 
bladder diveritculae, dysautonomia, low-normal IQ 
Autosomal Dominant CL  
(ADCL) 
ELN Autosomal 
Dominant 
Cutis laxa, valve stenosis & regurgitation, aortic dilation, emphysema, 
obstructive pulmonary disease, recurrent respiratory infections 
Autosomal Recessive CL Type 1 
(ARCL1) 
FBLN4 Autosomal 
Recessive 
Cutis laxa, emphysema, recurrent respiratory infections, arterial 
tortuosity, aortic dilation, hernias, joint laxity, arachnodactyly 
FBLN5 Autosomal 
Recessive 
Supravalvular aortic stenosis, emphysema, recurrent respiratory 
infections, hernias, cutis laxa 
Autosomal Recessive CL Type 2A 
(ARCL2A) 
ATP6V0A2 Autosomal 
Recessive 
Cutis laxa, large and/or delayed closure of fontanelles, eye anomalies, joint 
laxity, developmental delay 
Autosomal Recessive CL Type 2B 
(ARCL2B) 
PYCR1 Autosomal 
Recessive 
Cutis laxa (primarily on hands and feet), triangular shaped face, 
broad/prominent forehead, joint laxity, growth and developmental delay 
De Barsy Syndrome Unknown Autosomal 
Recessive 
Cutis laxa, joint laxity, joint dislocations, scoliosis, progeroid features, 
prominent forehead, large fontanelles, hypotonia, corneal opacification 
Urban-Rifkin-Davis Syndrome  
(URDS) 
LTBP4 Autosomal 
Recessive 
Cutis laxa, tachypnea, respiratory distress, emphysema, diverticulae, 
intestinal dilation/tortuosity, hernias, joint laxity, hypotonia, pulmonary 
artery stenosis 
MACS Syndrome RIN2 Autosomal 
Recessive 
Macrocephaly, alopecia, cutis laxa, scoliosis 
Acquired/Late-onset -- -- Adult onset cutis laxa, emphysema, aortic dilation, intestinal diverticulae, 
hernias 
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2.2 CHRONIC PULMONARY DISEASE 
Chronic pulmonary disease is a common cause of morbidity in the general population.  The 
different types are classified as either restrictive or obstructive.  Restrictive disease is 
characterized by a decrease in total lung capacity (TLC).  The two general types are chest wall 
disorders (e.g. neuromuscular disorders) and chronic interstitial and infiltrative disease (e.g. 
interstitial fibrosis) (Kuma et al 2009).  Obstructive lung diseases include conditions such as 
chronic obstructive lung disease (COPD), emphysema, chronic bronchitis, bronchiectasis, and 
asthma. 
2.2.1 Chronic Obstructive Pulmonary Disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is 
progressive and poorly reversible (ALA 2010, Barnes 2004, Celli et al 2004).  About 12.1 
million adults 18 years of age or older are estimated to have a diagnosis of COPD.  COPD is 
ranked as the fourth leading cause of death in the United States, with an age adjusted rate of 39.3 
per 100,000 with whites 1.6 times more likely than blacks and 2.5 times greater than Hispanics 
to be affected (ALA 2010).  A diagnosis, based on ICD-10 codes, includes COPD, chronic 
bronchitis, emphysema, and other lower chronic obstructive pulmonary diseases like 
bronchiectasis. 
The major pathological changes involve the central airways, peripheral airways, lung 
parenchyma, and pulmonary vasculature (Barnes 2004, Celli et al 2004).  Large airway changes 
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include hyperplasia of goblet cells and mucus gland enlargement (Shapiro & Ingenito 2005).  In 
addition, the alveolar attachments are disrupted, which causes airway closure during expiration.  
This leads to gas trapping in alveoli and hyperinflation (Barnes 2004).  Differences in 
mechanism and presenting anatomic changes dictate the type of obstructive disease (Kuma et al 
2009).   
2.2.1.1 Emphysema 
Emphysema is characterized by irreversible airspace enlargement with destruction of the alveolar 
walls (Kuma et al 2009).  In 2008, 3.8 million Americans reported a diagnosis of emphysema, 
with 94% of individuals older than 45 years of age (ALA 2010).  In 2009, 4.9 million (2.2%) 
noninstitutionalized adults reported ever being diagnosed with emphysema (CDC 2009).  The 
two types of emphysema most commonly seen in those with COPD are centrilobar and panacinar 
emphysema.  Centrilobar emphysema is characterized by the presence of microbullae in the 
center of the secondary lung lobule, and predominates in the upper lung zones.  This is a result of 
inflammation of the terminal and respiratory bronchioles, which leads to enlargement of the 
airspaces.  Panacinar emphysema is characterized by uniform destruction and enlargement of the 
airspaces, and predominates in the lower lung zones (Snider 2000).  Of note, clinical symptoms 
typically do not appear until at least one third of the parenchyma is damaged; symptoms include 
dyspnea, cough or wheezing (often confused with asthma). 
2.2.1.2 Chronic Bronchitis 
Bronchitis is characterized by the presence of hypersecretion of mucus (Hogg et al 2004, Kuma 
et al 2009).  Bronchitis is classified as chronic when hypersecretion of mucus and a persistent 
cough are present for at least three months in at least two consecutive years (Kuma et al 2009).  
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An estimated 3.8 million Americans were diagnosed with chronic bronchitis in 2008, with 
women twice as likely as men to be diagnosed.  In 2009, 9.9 million (4.4%) of 
noninstitutionalized adults reported ever being diagnosed with chronic bronchitis (CDC 2009).  
Onset is associated with inflammation and/or hyperplasia of the epithelium, gland ducts, and 
glands of the large central airways (Hogg et al 2004).  
2.2.1.3 Other Chronic Pulmonary Diseases 
Asthma 
The main signs and symptoms of asthma include episodic wheezing, a cough, chest tightness and 
dyspnea.  These symptoms are associated with bronchoconstriction that is reversible either with a 
bronchodilator or spontaneously.   Asthma primarily involves inflammation in all airways and 
mucus production, and does not involve the lung parenchyma (Kuma et al 2009, Barnes 2004).   
Asthma is considered a complex genetic disease with different causes and mechanisms, 
with genetic factors contributing the most to susceptibility.  Genome-wide linkage studies have 
identified over 100 genes associated with asthma and allergy.  Environmental risk factors include 
allergen sensitization, tobacco exposure, exposure to animals, and viral or bacterial infections 
(Subbarao et al 2009).  Factors in childhood that contribute to a poorer lung function in 
adulthood include early onset and/or more severe respiratory disease symptoms, persistent 
wheezing, low FEV1 values, and bronchial hyperresponsiveness.  It has been reported that longer 
duration of asthma is associated with more severe obstruction, indicating that duration is more 
important than age for the amount of obstruction in adulthood (Eisner et al 2010).   
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Bronchiectasis 
Bronchiectasis is characterized by the presence of large volumes of sputum and the presence of 
bronchial dilation and wall thickening.  The dilation is often permanent and caused by a 
breakdown of elastic tissue.  Symptoms and onset are commonly associated with respiratory tract 
infection (Celli et al 2004, Kuma et al 2009).  Symptoms include a cough, sputum, and fever. 
2.3 CUTIS LAXA & OBSTRUCTIVE PULMONARY DISEASE 
2.3.1 Elastin Threshold Hypothesis 
Shifren & Mecham (2006) presented data from elastin deficient mice.  They found that mice with 
at least 50% the amount of normal elastin are able to have normal lung development.  Mice with 
lower levels of elastin are at risk to develop severe lung disease, suggesting that susceptibility to 
lung disease or injury is influenced by the amount of normal elastin in the lung.  Finally, mice 
with 30% the amount of normal elastin have congenital emphysema.  Based on this data, they 
propose the elastin threshold hypothesis of lung injury.  
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Figure 1: Elastin Threshold Hypothesis of Lung Injury (Shifren & Mecham 2006). 
 
The threshold hypothesis is shown in Figure 1.  Because mice heterozygous for elastin 
mutations (ELN+/-) have normal lung development, the assumption is that the threshold of injury-
to-disease progression is lower than 50% (thick dashed line).  Those with normal elastin levels 
(top solid line) have the ability to repair lung injury.  When injury occurs in those with normal 
lung development and elastin deficiency, such as the ELN+/- mice (middle dotted line), the injury 
drops them below the threshold.  As a result they develop clinical disease, as seen in 10-15% of 
smokers who develop COPD.  Finally, those with a functional elastin level below the threshold 
(bottom dashed line), lung development is impaired causing congenital lung disease.  Shifren & 
Mecham (2006) suggest that this hypothesis may provide a model and explanation for the 
relationship between the extent of injury and amount of functional elastin. 
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2.3.2 Cutis Laxa & Pulmonary Disease 
Of the nine types of cutis laxa described, ADCL, ARCL1, URDS, and acquired/late-onset CL are 
noted to have significant pulmonary involvement.  The pulmonary involvement includes 
emphysema, history of pneumonia, recurrent respiratory infections, tachypnea, and respiratory 
distress.  Emphysema is noted to be a common pulmonary feature in all four of these types of 
cutis laxa.  The genes associated with these types include ELN, FBLN4, and LTBP4.   All three 
of these are components of elastic fibers.  Mutations in these genes have been shown, as 
previously discussed, to affect tropoelastin cross-linking and aggregation, conformation of other 
related elastic fiber components, and the stability of the elastic fiber.   Therefore, based on the 
discussion of lung development and threshold hypothesis, mutations in these genes may decrease 
the amount of available functional elastin causing congenital pulmonary disease or increase the 
risk of obstructive pulmonary disease like emphysema in cutis laxa patients. 
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3.0  SPECIFIC AIMS 
3.1 SPECIFIC AIM 1: DEFINE THE NATURAL HISTORY OF PULMONARY 
PHENOTYPES ASSOCIATED WITH CL. 
The purpose of this aim is to better characterize the pulmonary involvement within cutis laxa.  
This will allow for comparisons between the different ages of onset and between the different 
types of cutis laxa.  Such comparisons can lead to better classification, and for the determination 
of genotype-phenotype correlations. 
3.2 SPECIFIC AIM 2: DETERMINE IF HETEROZYGOTE CARRIERS OF SEVERE 
RECESSIVE CL MUTATIONS ARE SUSCEPTIBLE TO CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE (COPD). 
The genes known to cause cutis laxa are components of or involved in the formation of elastic 
fibers.  The loss of elasticity due to a break down or improper formation of elastic fibers is 
proposed to cause COPD.  As a result, loss of function of these involved proteins can lead to 
significant pulmonary disease in cutis laxa patients.  Due to this association, the purpose of this 
aim is to determine if mutations in one copy of a cutis laxa gene increase the risk for pulmonary 
disease. 
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4.0  METHODS 
The data used for this study was collected at University of Pittsburgh, Washington University of 
St. Louis, and University of Hawaii (previous IRB approval letters in Appendix A).  The 
protocol is currently funded by the National Heart, Lung, and Blood Institute.  The protocol is 
approved by University of Pittsburgh’s Institutional Board of Review (Appendix A).  Data was 
collected from 1999 until present.   
4.1 CLINIC PROTOCOL 
4.1.1 Recruitment 
Patients are primarily referred to our study by their treating physician, a genetic counselor, a 
member of the cutis laxa online support group, or they are self-refered.  Upon referral we invite 
these patients to participate.  First-degree relatives, specifically parents and children, are 
recruited through the participants already enrolled. 
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4.1.2 Screening 
Potential participants are contacted by phone to confirm their own or a first degree relative's cutis 
laxa diagnosis. They are asked if they or a first degree relative have (1) loose, lax skin, (2) skin 
in redundant folds, (3) inelastic (doughy) skin, (4) premature aging of the skin, (5) excessive 
premature wrinkling, or (6) another family member affected by cutis laxa.  If an individual has 
three or more of these features, their or their first degree relative's diagnosis will be considered to 
be confirmed.  We also ask whether the cutis laxa is congenital (present since birth or developed 
in early childhood) or acquired/late-onset (developed after early childhood). 
4.1.3 Informed Consent Process 
Individuals are able to participate either by attending a research clinic at University of Pittsburgh 
Medical Center or through their treating physician.  For individuals who attend one of the 
research clinics, prior to their study visit a letter explaining the study and the procedures that will 
be performed is sent.  At the study visit informed consent is obtained.  For individuals who will 
not attend one of the research clinics, the study will be explained to the subject over the phone.  
During this process, the information included in the consent form is orally communicated. 
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4.1.4 Research Activities 
4.1.4.1 Research Clinic Involvement for Affected Individuals 
The research clinic is a multidisciplinary clinic.  A genetic evaluation and physical exam is 
performed on all individuals who attend the clinic. Other evaluations and testing involved in the 
clinic includes cardiovascular, pulmonary, skeletal, and hearing assessments.   
The genetic evaluation includes measurements, such as the patient's height and weight, as 
well as general observations about the subject's overall health and appearance.  As part of this 
evaluation a clinical questionnaire is completed.  The questionnaire (Appendix B) collects 
information regarding a patient’s medical and family history.  Responses indicate the presence or 
absence of common cutis laxa clinical features, and features of related disorders.  This allows for 
confirmation of a cutis laxa diagnosis.   All questionnaires are entered into a database after the 
clinic.  Finally samples are collected, which include 30 ml of blood and two 3 mm skin biopsies.  
If blood draw is unsuccessful or declined by the patient, a saliva sample may be collected instead 
of a blood sample. 
A cardiovascular evaluation consisting of an echocardiogram is performed on those age 
13 years or older.  The echocardiogram is performed by a trained technician and the results are 
interpreted by a physician.  A report is generated which includes impressions and measurements.   
The pulmonary evaluation involves a self-administered respiratory health questionnaire, 
pulmonary function test, and chest CT.  All patients complete the respiratory health 
questionnaires, and assistance is provided if needed.  The questionnaires ask about the patient’s 
history of breathing problems and environmental exposures.  The pulmonary function tests are 
only performed in patients older than 5 years of age.  In addition, only adult patients without 
cardiovascular disease are tested for bronchodilator responses.  Finally, only adult patients, those 
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18 years of age and older, have a chest CT.  All three aspects are evaluated by members of the 
research team. 
A hearing test is performed on patients older than 6 years of age. The test involves the 
following: otoscopy, tympanometry, behavioral hearing, frequency-sweep distortion-product 
otoacoustic emissions (DPOAE) (measure of cochlear integrity), DPOAE Input/Output (measure 
of cochlear compression), and contralateral-suppression DPOAE (measure of lower-brainstem 
integrity). 
The skeletal evaluation consists of a DEXA scan.  The DEXA scan is only performed on 
adult patients, those 18 years of age or older.  The report generated provides images, 
measurements, z-scores, and indicates if whether the patient has normal bone density, 
osteopenia, or osteoporosis.  
Recent additions to the protocol include 3D facial image and elasticity testing.  The facial 
imaging involves a portable 3D stereophotogrammetry system that uses six overlapping cameras 
to capture the face at different angles.  This helps to better characterize the facial features and 
structure of those with cutis laxa.  The elasticity testing involves a measurement of skin elasticity 
and an estimate of blood vessel elasticity.  The skin elasticity is measured on the arms of each 
patient.  The blood vessel estimate is obtained through pulse wave analysis and pulse wave 
velocity.  
This is a biannual research clinic for individuals affected with cutis laxa and individuals 
who have a first-degree relative affected with cutis laxa. The clinic takes place over several days, 
and each participant receives individual appointments for the above evaluations.  
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4.1.4.2 Non-Research Clinic Involvement for Affected Individuals 
For affected individuals who do not attend the research clinic, the following describes the 
process for their involvement.  Patients with the help of their treating physician are asked to fill 
out the clinical questionnaire.  In addition a dermatological and/or genetic evaluation with 
clinical photographs is performed by the patient’s referring or primary care physician as part of 
their standard of care.  Any of the following materials (blood, skin biopsy, saliva, banked DNA, 
tissue sample removed as part of surgical treatment) that have already been collected by the 
participant's physician will be requested and subsequently sent to our laboratory. If these 
samples, specifically blood, saliva, and/or skin biopsy, have not been collected as part of 
standard of care, we ask physicians to collect these. 
Additionally, if patients have had an echocardiogram or pulmonary function test within 
the year prior to enrollment, we ask for copies of these reports.  When these tests have not been 
performed within the year prior to enrollment, we ask their treating physician order these tests 
and to send copies of these reports. Pulmonary function tests will only be asked to be performed 
in subjects older than 5 years. 
4.1.4.3 Research Activities for Unaffected First Degree Relatives 
When a first-degree relative is deemed unaffected (does not meet the inclusion criteria for 
affected cutis laxa participants, see section “Screening”) either a blood or saliva sample will be 
collected for genetic testing.  A first-degree relative found to have a mutation in a cutis-laxa-
causing gene is asked to participate in the research activities as already described above for those 
who attend a research clinic or for those who do not attend the research clinic.  When a mutation 
is not identified, the relative is not asked to participate in additional research activities. 
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4.1.5 Follow-up 
 As part of the current protocol participants are contacted yearly for at least five years to obtain 
updated medical information on the individual's condition.  The purpose is to follow the 
progression of disease.  The annual follow-ups will be conducted over the phone. The principal 
investigator or one of the study coordinators ask about any changes in the research subject's 
health status. If any additional evaluations or exams have been performed, copies of the reports 
will be requested.  Patients are also encouraged to contact a member of the research team with 
questions or if they wish to provide more often updates on changes in their health. 
In addition to annual phone calls, patients are welcome to participate in future research 
clinics. If they attend additional research clinics we ask them to participate in the same testing 
that they participated at their initial visit, and to participate in any new testing. This allows us to 
monitor if there has been any progression of disease if the initial test was abnormal, also if new 
symptoms have presented, or if the patient has remained stable. 
4.1.6 Mutational Analysis 
Sources of DNA for mutational analysis include peripheral blood, skin fibroblasts, or saliva 
samples.  A standard DNA isolation method used which involves lysis of nuclei and 
deproteination of DNA.  For mutational analysis, gene specific primers were developed for PCR 
amplification.  PCR reactions are carried out using the thermal cycler GeneAmp PCR System 
9700 (Applied Biosystems, Foster City, CA, USA).  All PCR products are purified with 
ExoSAP-IT, and then prepared for sequencing using ABI BigDye Terminator Kit (Applied 
Biosystems, Foster City, CA, USA).  Sequences of both sense and antisense strands are 
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compared with reference gene sequences with UCSB Genomic Brower or Sequencher software 
(GeneCodes, Ann Arborm MI, USA).  Confirmation is obtained by identification of a mutation 
in at least two independent amplification products.  
4.2 PULMONARY DATA 
For this study, information collected from the clinical questionnaire and pulmonary function tests 
(PFTs) were used.  Due to limited numbers of chest CTs, they were excluded from this analysis.  
Inclusion was limited to patients and first-degree relatives with completed clinical questionnaires 
or detailed medical histories. 
4.2.1 Patient Classifications 
4.2.1.1 Onset Classification 
All affected patients were classified as congenital, acquired/late-onset, and unknown.  
Requirements for each classification are based on age of onset and mutational status: 
(1) Congenital: (A) Skin features noted to be present at birth; (B) Clinical questionnaire 
completed or medical history obtained under the age of 5 years, with confirmation of 
cutis laxa based on the study inclusion criteria; (C) Known gene mutation in a cutis laxa 
causative gene. 
(2) Acquired/Late-onset: (A) Skin features developed in adolescence or adulthood; (B) No 
gene mutation; (C) No affected family members. 
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(3) Unknown: (A) Clinical questionnaire or medical history obtained above the age of 5 
years and did not indicate age of onset of skin features; (B) Multiple affected family 
members in at least two generations with onset of skin features after the age of 5 years, 
and no gene mutation. 
Classifying patients by onset allows for comparison of type, severity, and/or progression of 
pulmonary complications. 
4.2.1.2 Cutis Laxa Type 
If a mutation was identified in a cutis laxa causative gene in a patient, they were classified as 
having the associated type of cutis laxa.  Unaffected first-degree relatives with an identified 
mutation were classified as carriers for the related type of cutis laxa.  Table 2 lists the genes and 
types of cutis laxa. For patients with no identified mutation, they were classified only by onset 
(congenital, acquired/late-onset, unknown) as previously described.  
 
Table 2: Cutis Laxa Types & Genes. 
Type OMIM# Gene OMIM# 
OHS 304150 ATP7A 300011 
ADCL 123700 ELN 130160 
ARCL1 219100 
FBLN4 
FBLN5 
604633 
604580 
ARCL2A 219200 ATP6V0A2 611716 
ARCL2B 612940 PYCR1 179035 
URDS 613177 LTBP4 604710 
MACS 613075 RIN2 610222 
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4.2.2 Clinical Questionnaires & Medical Histories 
Clinical questionnaires and detailed medical histories have been collected from patients for the 
past 12 years.  Clinical questionnaires were completed by the patient’s referring physician or 
genetic counselor, a member of our research group, or the patient.  Detailed medical histories 
were obtained from either medical records or the patient.  The questionnaire responses and 
information from medical histories were entered into a database. 
Over the past 12 years, the clinical questionnaire has evolved to include additional 
questions.  Figure 2, Figure 3, and Figure 4 represent the progression of the respiratory section of 
the questionnaire (See Appendix B for the complete 2011 Cutis Laxa Questionnaire).  Additions 
consisted of common answers written next to the respiratory section or additional comments 
section. 
 
RESPIRATORY: 
Bronchiectasis:  Yes  [ ]       No  [ ]       ?  [ ] 
Hypoplastic lungs (newborn): Yes  [ ]       No  [ ]       ?  [ ] 
Emphysema:   Yes  [ ]       No  [ ]       ?  [ ] 
Tachypnea:   Yes  [ ]       No  [ ]       ?  [ ] 
Pneumonia:   Yes  [ ]       No  [ ]       ?  [ ] 
 
Figure 2: 1999-2004 CL Questionnaire: Respiratory Section. 
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RESPIRATORY: 
Bronchiectasis:  Yes  [ ]       No  [ ]       ?  [ ] 
Hypoplastic lungs (newborn): Yes  [ ]       No  [ ]       ?  [ ] 
Emphysema:   Yes  [ ]       No  [ ]       ?  [ ] 
Tachypnea:   Yes  [ ]       No  [ ]       ?  [ ] 
Pneumonia:   Yes  [ ]       No  [ ]       ?  [ ] 
Chest CT findings and date: _________________________________________ 
Current smoker:  Yes  [ ]       No  [ ]        
Cigarette packs per day:  ___________________________ 
Years smoked:  ___________________________ 
 
 
Figure 3: 2004-2010 CL Questionnaire: Respiratory Section.  Additions include chest CT 
findings and date, smoking status, and smoking history. 
 
RESPIRATORY: 
Bronchiectasis:  Yes  [ ]       No  [ ]       ?  [ ] 
Hypoplastic lungs (newborn): Yes  [ ]       No  [ ]       ?  [ ] 
Emphysema:   Yes  [ ]       No  [ ]       ?  [ ] 
Tachypnea:   Yes  [ ]       No  [ ]       ?  [ ] 
Pneumonia:   Yes  [ ]       No  [ ]       ?  [ ] 
Asthma:   Yes  [ ]       No  [ ]       ?  [ ] 
Chest CT findings and date: _________________________________________ 
Pulmonary function test (PFT) findings and date:  ___________________________ 
 
Current smoker:  Yes  [ ]       No  [ ]        
Cigarette packs per day:  ___________________________ 
Years smoked:  ___________________________ 
Other respiratory findings: 
 
Figure 4: 2011 CL Questionnaire: Respiratory Section.  Additions include asthma, PFT 
findings and date, and other respiratory findings. 
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Due to differences in the clinical questionnaires collected, responses other than those 
asked on the first questionnaire (Figure 2: bronciectasis, hypoplastic lungs, emphysema, 
tachypnea, and pneumonia) were only counted if more than two patients noted a history of the 
condition.  In addition, if the response “?” was checked, it was counted as an absence of a 
diagnosis or history of the condition. 
4.2.3 Pulmonary Function Tests (PFTs) 
PFTs were primarily obtained at research clinics, which have been held at Washington 
University of St. Louis in 2008 and University of Pittsburgh in 2010.  All other PFTs came from 
received medical records.  At this time PFTs have only been obtained on a subset of the patients 
and unaffected first degree relatives.   
4.2.3.1 Pulmonary Function Classification 
To assess pulmonary function, the algorithm defined by the American Thoracic Society 
(ATS)/European Respiratory Society (ERS) Task Force was used (Pellegrino et al 2005). 
Determination and diagnosis of pulmonary function abnormality is based on the spirometry 
parameters forced vital capacity (FVC), forced expiratory volume in one second (FEV1), 
FEV1/FVC ratio, and total lung capacity (TLC).  The types of pulmonary function abnormalities 
include normal, obstruction, restriction, and mixed defect.  The diagnosis of the three types is 
based on lower limits of normal (LLN; parameter measurement less than the 5th percentile of 
predicted), see Figure 5: 
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(1) Normal: FEV1/FVC > LLN & FVC > LLN 
(2) Obstruction: (A) FEV1/FVC < LLN & FVC > LLN; (B) FEV1/FVC < LLN, FVC < LLN, 
& TLC > LLN; or (C) FEV1/FVC > LLN, FVC < LLN, & TLC > LLN 
(3) Restriction: FEV1/FVC > LLN, FVC < LLN, & TLC < LLN 
(4) Mixed defect (Obstruction & Restriction are present): FEV1/FVC < LLN, FVC < LLN, & 
TLC < LLN 
 
Figure 5: ATS/ERS algorithm to assess lung function in clinical practice (Pellegrino et al. 2005). 
 
To determine the LLN for the spirometry parameters, published reference values were 
used.  Reference equations developed by Hankinson, Odencrantz, and Fedan (1998) from the 
third National Health and Nutrition Examination Survey (NHANES III) were used for FVC, 
FEV1, and FEV1/FVC (Appendix C).  Reference values and LLNs are applicable for those aged 
8-80 years of age, and are specific for gender (male vs. female), and three race/ethnicity groups 
(Caucasian, African-American, and Mexican-American).  For TLC, reference values and 
equations developed by Stocks & Quanjer (1995) from published data were used for 
determination of LLN (Appendix C).  Equations and values are specific for gender (male vs. 
female), and by age (Children & adolescence: age 8-18 years; Adult: age 18-70 years). 
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4.3 STATISTICAL ANALYSIS 
Descriptive statistics were used to determine the frequencies for the categorical data.  Categorical 
data includes types of responses (presence or absence of diagnosis), lung function classification 
for type of CL onset, and mutational status.  To compare the categorical data, either Fisher’s 
exact test or a Chi-square analysis was performed.  The PFT parameters FVC (% predicted), 
FEV1 (% predicted), and FEV1/FVC (%) between the types of CL onset were compared using 
analysis of variance (ANOVA).  A significance of 0.05 was used for Fisher’s exact test, Chi-
square, and ANOVA.  
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5.0  RESULTS 
A total of 94 questionnaires and medical histories have been collected over the past 12 years.  
Questionnaires and medical histories were obtained on individuals with a confirmed or suspected 
diagnosis of CL (patients), and unaffected first-degree relatives.  Of the 94 questionnaires and 
medical histories, 6 were excluded from this analysis.  Reasons for exclusion included an 
unconfirmed diagnosis of CL, unaffected first-degree relatives with no mutation (thus, not 
carriers), or incomplete respiratory responses.  Therefore, for analysis of respiratory responses 
and histories, 88 were used.  This included 83 patients with confirmed or suspected CL and 5 
unaffected first-degree relatives with mutations (carriers). 
5.1 GENERAL PULMONARY RESPONSES 
The types and frequency of respiratory responses and histories (referred to as pulmonary 
condition) were analyzed (Appendix D shows responses for each patient).  As described, the core 
respiratory questions asked about the presence or absence of bronchiectasis, hypoplastic lung, 
emphysema, tachypnea, or pneumonia.  Other responses included in the analysis were a history 
of obstructive apnea, respiratory distress, bronchitis, and dyspnea.  These were included because 
at least three patients noted a diagnosis or history of these pulmonary conditions.  The most 
common responses amongst all participants were a history of pneumonia (24.1%), diagnosis of 
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tachypnea (15.7%), or a diagnosis of emphysema (12.0%).  All other responses had a frequency 
of 3.61-7.23% (Table 3 and Figure 6).  
 
Table 3: Pulmonary Responses for All Participants (N = 83) 
Pulmonary Condition Response Frequency Percent (%) 
Bronchiectasis Yes 3 3.61 
No 80 96.4 
Hypoplastic lung Yes 3 3.61 
No 80 96.4 
Emphysema Yes 10 12.0 
No 73 88.0 
Tachypnea Yes 13 15.7 
No 70 84.3 
Pneumonia Yes 20 24.1 
No 63 75.9 
Asthma Yes 6 7.23 
No 77 92.8 
Obstructive Apnea Yes 4 4.82 
No 79 95.2 
Respiratory Distress Yes 3 3.61 
No 80 96.4 
Bronchitis Yes 3 3.61 
No 80 96.4 
Dyspnea Yes 4 4.82 
No 79 95.2 
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Figure 6: Pulmonary Responses for All Patients. 
 
The prevalence of emphysema in our CL cohort was then compared to the prevalence of 
emphysema in the general population.  Data for the prevalence in the general population was 
obtained from the 2009 National Health Interview Survey (NHIS) conducted by the Centers for 
Disease Control and Prevention (CDC).  As indicated in Table 4, the frequency of emphysema 
was 12.0% in our CL cohort, compared to 2.2% in the general population.  Chi-square analysis 
revealed a p-value of 5.47E-10, indicating that the prevalence of emphysema in our CL cohort is 
significantly higher than the general population. 
 
Table 4: Comparison of Emphysema Prevalence Between CL & General Population. 
Pulmonary 
Condition 
Response 
CL Cohort General Population 
p-value 
Frequency Percent (95% CI) Frequency Percent (95% CI) 
Emphysema 
Yes* 10 12.0% (5.0-19.0) 4895 2.2% (2.09-2.21) 5.47E-10 
No 73 
 
222,476 
  
Total 83 
 
227,371 
  
* “Yes” indicates that the individual has been diagnosed with emphysema. 
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5.2 ONSET CLASSIFICATION AND PULMONARY RESPONSES 
Classification of onset was determined as previously described.  Of the 83 patients, 8 (9.64%) 
were acquired/late-onset, 52 (62.7%) were congenital, and 23 (27.1%) were unknown.  The types 
of respiratory responses and histories are shown in Table 5 and Figure 7.  At least one congenital 
patient indicated a history of a pulmonary condition for each response, with 27/52 (51.9%) 
congenital patients individually reporting a diagnosis or history of at least one pulmonary 
condition.  The most common response of congenital patients was a history of pneumonia 
(23.1%), which is the most common response overall.  The other common response for 
congenital patients was tachypnea (21.1%).  Congenital patients accounted for 11/13 (84.6%) of 
all tachypnea responses.  Patients classified as unknown provided similar responses to the 
congenital group, with 10/23 (43.5%) reporting at least one response.  For acquired/late-onset, 
the only responses were emphysema (12.5%), pneumonia (25.0%), and dyspnea (37.5%), with 
4/8 (50.0%) patients accounting for all responses. 
For comparison of responses between the three groups of onset (acquired/late-onset, 
congenital, and unknown), only dyspnea was of statistical significance (p = 0.0023) (Table 5).  
Acquired/late-onset patients reported a significantly increased prevalence of dyspnea compared 
to other groups, accounting for 3/4 (75.0%) of all dyspnea responses.   
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Table 5: Pulmonary Responses by Onset Classification (N = 83). 
 
Pulmonary 
Condition 
Response Acquired / Late-onset (%)* Congenital (%)* Unknown (%)* p-value 
Bronchiectasis 
Yes 0 3 (5.77) 0 
0.6681 
No 8 49 23 
Hypoplastic lung 
Yes 0 2 (3.85) 1 (4.35) 
1.000 
No 8 50 22 
Emphysema 
Yes 1 (12.5) 6 (11.5) 3 (13.0) 
1.000 
No 7 46 20 
Tachypnea 
Yes 0 11 (21.2) 2 (8.70) 
0.2598 
No 8 41 21 
Pneumonia 
Yes 2 (25.0) 12 (23.1) 6 (26.1) 
0.9269 
No 6 40 17 
Asthma 
Yes 0 4 (7.69) 2 (8.70) 
1.000 
No 8 48 21 
Obstructive 
Apnea 
Yes 0 3 (5.77) 1 (4.35) 
1.000 
No 8 49 22 
Respiratory 
Distress 
Yes 0 3 (5.77) 0 
0.6681 
No 8 49 23 
Bronchitis 
Yes 0 2 (3.85) 1 (4.35) 
1.000 
No 8 50 22 
Dyspnea 
Yes 3 (37.5) 1 (1.92) 0 
0.0023 
No 5 51 23 
*Percentages represent the percent of patients within the type of onset who responded "Yes" to the type of 
pulmonary condition. 
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Figure 7: Pulmonary Responses by Onset Classification. 
5.3 MUTATIONAL ANALYSIS 
Mutations have been identified in 27 patients and 5 unaffected first-degree relatives (carriers) of 
the 88 questionnaires and medical histories analyzed. Mutational analysis identified mutations in 
ELN, FBLN4, FBLN5, ATP6V0A2, and LTBP4 (Table 6).  Table 7 indicates the type of CL, gene, 
mutational status, type of mutation(s), and if the case has previously been described in literature.   
For patients with mutations, 7 have ADCL (ELN mutation), 2 have ARCL1 (FBLN4 or FBLN5 
mutation), 5 have ARCL2A (ATP6V0A2 mutation), and 13 have URDS (LTBP4 mutation).  For 
LTBP4, only one mutation has been identified in 6 of the 13 patients.  Even though only one 
mutation has been identified, based on clinical findings, these patients have been classified as 
having URDS.  For unaffected first-degree relatives, 3 are URDS carriers and 2 are ARCL1 
carriers.  
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Table 6: Pulmonary Responses by CL Type (Mutational Status) (N = 32). 
Pulmonary 
Condition 
Response 
ADCL (%)* ARCL1 (%)* ARCL2A (%)* URDS (%)* 
 
p-value 
ELN FBLN4 / FBLN5 ATP6V0A2 LTBP4 
Affected Affected Carrier Affected Affected Carrier 
Bronchiectasis 
Yes 0 0 0 1 (20.0) 2 (15.4) 0 
0.7982 
  No 7 2 2 4 11 3 
Hypoplastic 
lung 
Yes 0 0 0 0 2 (15.4) 0 
0.8165 
  No 7 2 2 5 11 3 
Emphysema 
Yes 0 1 (50.0) 0 0 0 0 
0.3608 
  No 7 1 2 5 13 3 
Tachypnea 
Yes 1 (14.3) 0 0 0 7 (53.9) 1 
0.1675 
  No 6 2 2 5 6 2 
Pneumonia 
Yes 2 (28.6) 0 1 (50.0) 1 (20.0) 4 (30.8) 2 (66.7) 
0.7354 
  No 5 2 1 4 9 1 
Asthma 
Yes 2 (28.6) 0 0 0 1 (7.69) 1 (33.3) 
0.4686 
  No 5 2 2 5 12 2 
Obstructive 
Apnea 
Yes 0 0 0 0 1 (7.69) 1 (33.3) 
0.5282 
  No 7 2 2 5 12 2 
Respiratory 
Distress 
Yes 0 0 0 0 1 (7.69) 0 
1.000 
  No 7 2 2 5 12 3 
Bronchitis 
Yes 0 0 0 0 1 (7.69) 1 (33.3) 
0.5282 
  No 7 2 2 5 12 2 
Dyspnea 
Yes 0 0 0 0 1 (7.69) 0 
1.000 
  No 7 2 2 5 12 3 
* Percentages represent the percent of patients within the CL type/mutational status who responded “Yes” to the 
type of pulmonary condition. 
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Table 7: Mutational Status of Patients and Carriers. 
CL Onset 
Classification 
Type of 
CL 
Gene Status Genomic cDNA Protein Type of 
Mutation(s) 
Publication 
Carrier URDS 
Carrier 
LTBP4  Heterozygote g. + / 12666+1G>T c. + / 883+1G>T  p. + / ?  + / Intronic   
Carrier URDS 
Carrier 
LTBP4  Heterozygote g. + / 18711C>T c. + / 2161C>T p. + / R721X  + / Nonsense   
Carrier URDS 
Carrier 
LTBP4  Heterozygote g. + / 12666+1G>T c. + / 883+1G>T  p. + / ?  + / Intronic   
Carrier ARCL1 
Carrier 
FBLN4  Heterozygote   c. + / 169G>A p. + / E57K  + / Missense Hucthagowder et al. (2006) 
Carrier ARCL1 
Carrier 
FBLN4  Heterozygote   c. + / 169G>A p. + / E57K  + / Missense Hucthagowder et al. (2006) 
Congenital ADCL ELN  Heterozygote    + / 2159delC   Deletion Szabo et al. (2006) 
Congenital ADCL ELN  Heterozygote    + / 2112_2136del   Deletion Szabo et al. (2006) 
Congenital ADCL ELN  Heterozygote    + / 2112_2136del   Deletion Szabo et al. (2006) 
Congenital ADCL ELN  Heterozygote   c. +/2318G>A p. +/G773D Missense   
Congenital ADCL ELN  Heterozygote   c. +/2318G>A p. +/G773D Missense   
Congenital ADCL ELN  Heterozygote   c. +/2177delC    Deletion   
Congenital ADCL ELN  Heterozygote   c. +/2177delC   Deletion   
Congenital ARCL1 FBLN4  Homozygote   c. 169G>A /  169G>A p. E57K /  E57K Missense Hucthagowder et al. (2006) 
Congenital ARCL1 FBLN5  Homozygote   c. 649T>C / 649T>C p. C217R / 
C217R 
Missense Claus et al. (2008) 
Congenital ARCL2A ATP6V0A2  Homozygote g. 40006_40084dup / 
40006_40084dup 
c. 2096_2174dup / 
2096_2174dup 
p. E725fsX745 / 
E725fsX745 
Frame-shift Hucthagowder et al. (2009) 
Congenital ARCL2A ATP6V0A2  Homozygote g. 31487_31488insC / 
31487_31488insC 
c. 1058_1059insC / 
1058_1059insC 
p. I353fsX432 / 
I353fsX432 
Frame-shift Hucthagowder et al. (2006) 
Congenital ARCL2A ATP6V0A2  Homozygote g. 42220C>T / 42220C>T c. 2293C>T / 2293C>T p. Q765X / 
Q765X 
Nonsense Kornak et al. (2008) 
Congenital ARCL2A ATP6V0A2   Compound  
Heterozygote 
g. 326_327insC / 10097C>T c. 78_79insC / 260 C>T p.S27fsX54 / 
P87L 
Frame-shift / 
Missense 
Hucthagowder et al. (2006) 
Congenital ARCL2A ATP6V0A2   Compound  
Heterozygote 
g. 12439_12440insCATGCTGA 
/ 45608A>G 
c. 397_398insCATGCTGA 
/ 2466_2470delGGTAG 
p. R133fsX135 / 
W822X 
Frame-shift / 
Nonsense 
Hucthagowder et al. (2006) 
Congenital URDS LTBP4  Compound 
Heterozygote  
g. 12666+1G>T / 18711C>T c. 883+1G>T / 2161C>T p. ? / R721X Intronic / 
Nonsense 
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Table 7 (Continued). 
Congenital URDS LTBP4  Compound  
Heterozygote  
g. 30850T>A / 19015insA c. 3856T>A / 2377insA p. C1286S / 
G793fsX797 
Missense / Frame-
shift 
  
Congenital URDS LTBP4  Compound 
 Heterozygote 
  c. 1242C>T/ 4114dupC p. R448X/ 
A1372fsX2 
Nonsense / Frame-
shift 
  
Congenital URDS LTBP4  Compound 
 Heterozygote 
g.12574 / 
20287_20288delGCinsAA 
c. 791delC / 
2570_2571delGCinsAA 
p. P264fsX300 / 
C857X 
Frame-shift / 
Nonsense 
Urban et al. (2009) 
Congenital URDS LTBP4  Homozygote g. 12603T>G / 12603T>G c. 820T>G / 820T>G  p. C274G / 
C274G 
Missense Urban et al. (2009) 
Congenital URDS LTBP4  Compound  
heterozygote 
g. 20287_20288delGCinsAA / 
33861insC 
c. 2570_2571delGCinsAA / 
4128insC 
p. C857X / 
P1376fsX1403 
Nonsense / Frame-
shift 
Urban et al. (2009) 
Congenital URDS LTBP4  Homozygote g. 29481delA / 29481delA  c. 3554delA / 3554delA p. 
Q1185fsX1211 / 
Q1185fsX1211 
Frame-shift Urban et al. (2009) 
Congenital URDS LTBP4  Heterozygote g. ? / 17384C>G c. ? / 1792C>G p. ? / R598G ? / Missense   
Congenital URDS LTBP4  Heterozygote g. ? / 18229G>A c. ? / 2143G>A p. ? / D715N ? / Missense   
Congenital URDS LTBP4  Heterozygote g. ? / 23820C>G c. ? / 2099C>G p. ? / P1032R ? / Missense   
Congenital URDS LTBP4  Heterozygote g. ? / 33861insC c. ? / 4128insC p. ? / 
P1376fsX1403 
? / Frame-shift   
Congenital URDS LTBP4  Heterozygote g. ? / 36305C>T  c. ? / 4685C>T p. ? / S1562F ? / Missense   
Congenital URDS LTBP4  Heterozygote  g. ? / 33841C>G c. ? / 4108 C>G p. ? / P1370A ? / Missense   
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5.3.1 Mutational Analysis and Pulmonary Responses 
Within ADCL, ARCL1, ARCL2A, and URDS and carriers of ARCL1 and URDS at least patient 
reported a diagnosis or history of at least one pulmonary condition (Table 7, Figure 8).  Of 
ADCL patients, 3/7 (42.9%) reported pulmonary complications and the responses were 
tachypnea, pneumonia, and asthma.  For ARCL1, the patient with FBLN4 mutation was noted to 
have emphysema.  This was already known, due to this case being previously described by 
Hucthagowder et al. (2006).  One of the carriers of ARCL1, who is a parent of the FBLN4 
patient, reported a history of pneumonia.  For ARCL2A, 1 patient had a history of bronchiectasis 
and 1 patient had a history of pneumonia, therefore 2/5 (40.0%) noted pulmonary complications.  
Finally, for URDS, all but emphysema was reported as a pulmonary complication for URDS 
patients.  In addition, 10/13 (76.9%) of URDS patients reported a diagnosis or history of at least 
one pulmonary condition.  Of the 3 URDS carriers, 1 had a history of bronchitis, obstructive 
apnea, asthma, tachypnea, and pneumonia.  Comparison of pulmonary responses between the CL 
types, including patients and carriers, indicated no statistically significant associations. 
Comparison of pulmonary responses with the exclusion of carriers also did not indicate any 
statistically significant associations (Data available in Appendix D). 
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Figure 8: Pulmonary Responses by CL Types (Mutational Status). 
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5.4 PULMONARY FUNCTION TEST (PFT) RESULTS 
PFTs have been obtained on 13 of the 88 patients and carriers with questionnaires or medical 
histories.  Of the 13, 4 are acquired/late-onset, 5 are congenital, 1 is unknown, and 3 are carriers 
(Table 8).  The 3 carriers are URDS carriers, 3 of the congenital patients have an ELN mutation, 
and 1 of the congenital patients has an ATP6V0A2 mutation.  The type of airway limitation 
(pulmonary function classification: obstruction, restrictive, mixed defect) was determined for 
each patient and carrier using the ATS criteria already described.  Based on these criteria, which 
uses the PFT parameters FVC, FEV1, FEV1/FVC, and TLC, obstruction was the only type of 
airway limitation (PFT parameter results available in Appendix D).  Within the 4 groups, 4/4 
(100.0%) of acquired/late-onset patients have obstruction, 3/5 (60.0%) of congenital patients 
have obstruction, and the unknown patient and all carriers had normal pulmonary function 
(Figure 9).  Of note, these 4 acquired/late-onset patients were the same 4 patients who account 
for all pulmonary responses on questionnaires and medical histories. Comparison of the normal 
pulmonary function vs. obstruction between the three groups with Fisher’s exact test indicated no 
statistically significant difference.  In addition, comparison of means of the parameters FVC (% 
predicted), FEV1 (% predicted), and FEV1/FVC (%) between acquired/late-onset, congenital, and 
unknown indicated no statistically significant differences. 
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Table 8: Pulmonary Function Classification 
 
Onset Classification Gene Pulmonary Function Classification Degree of Severity 
Acquired/Late-onset -- Obstruction Mild 
Acquired/Late-onset -- Obstruction Mild 
Acquired/Late-onset -- Obstruction Severe 
Acquired/Late-onset -- Obstruction Very Severe 
Congenital ELN  Normal -- 
Congenital ELN  Obstruction Moderate 
Congenital ELN  Obstruction  Mild 
Congenital ATP6V0A2 Obstruction Moderate 
Congenital -- Normal -- 
Unknown -- Normal -- 
Carrier LTBP4  Normal -- 
Carrier LTBP4  Normal -- 
Carrier LTBP4  Normal -- 
 
 
Figure 9: Pulmonary Function Classification. 
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6.0  DISCUSSION 
The purpose of this study was to better characterize the pulmonary phenotype of CL.  Previously, 
the pulmonary complications associated with CL have only been described in case studies of 
patients and reviews of specific CL types (as described in the “Background”).  The majority of 
these reports have indicated obstructive lung disease and recurrent infections as the common 
findings.  This study provides a preliminary analysis of the pulmonary involvement within and 
among the different types of CL.  For this, clinical data collected from clinical questionnaires 
and medical histories on 83 patients with a confirmed or suspected diagnosis of CL was 
analyzed.  In addition, 13 pulmonary function tests (PFTs) were collected on 10 patients and 3 
unaffected first-degree relatives with a known mutation (carriers).  Of importance, this is the 
largest group of CL patients described to date.   Even though there are few statistically 
significant findings, this study helps better define the pulmonary disease found in CL.  This 
study demonstrated that there is clinical overlap of the pulmonary complications between the 
different types of CL based on onset and mutational status. 
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6.1 GENERAL PULMONARY RESPONSES 
The most common reported respiratory diagnoses amongst all of the CL patients were 
pneumonia (24.1%), tachypnea (15.7%), and emphysema (12.0%).   Pneumonia and emphysema 
are both common causes of morbidity within the United States.  For instance, 2.2% of 
noninstitutionalized adults reported a diagnosis of emphysema (CDC 2009).  This is in 
comparison to our group of CL patients in which 12.0% reported a diagnosis of emphysema.   
The difference in prevalence of emphysema between our CL cohort and the general 
population was determined to be statistically significant.  Therefore, this suggests that 
individuals with CL are more likely to develop emphysema compared to the general population.  
In respect to individuals with CL, this indicates the importance of pulmonary evaluations and 
continual screening due to the health complications associated with emphysema.  In addition, the 
higher prevalence exhibits the potential involvement of CL causative genes in the pathogenesis 
of emphysema.  Therefore, determining the etiology of emphysema in CL may provide valuable 
information on emphysema for the general population. 
A history of respiratory infections like pneumonia is important because it has been shown 
to be associated with obstructive lung disease (Gracia-Vidal et al. 2009).  With COPD, it has 
been shown to predispose people to community acquired pneumonia, and those with COPD are 
more likely to have recurrent infections.  In addition, patients with COPD who have chronic 
bronchitis with recurrent respiratory infections were shown to have lower levels of the 
complement components C3 and C4 compared to healthy subjects (Kosmas et al. 1997).  A low 
level of complement components is indicative of sustained activation due to the presence of 
infection.  An infection and sustained activation may be related to decrease in ability to clear 
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infection (Meyer 2004).  Cough and mucociliary clearance are lower respiratory tract mechanical 
defenses against infectious agents and help to remove aspirated or inhaled agents.  Inflammation, 
breakdown of the alveoli, and/or a decrease in elastic recoil (due to loss or lack of elasticity) may 
interfere with the lungs ability to perform these clearance mechanisms (Kosmas et al. 1997).  
The incidence of pneumonia among CL patients may be related to a similar mechanism of 
decreased ability to clear infections.  Whether this is related to obstruction or a decrease in the 
elastic recoil is unknown at this time. 
Tachypnea, or increased respiratory rate, is most often caused by hypoxemia.  Conditions 
that can cause hypoxemia, thus tachypnea, include, but are not limited to, pneumonia, asthma, 
COPD, pulmonary edema, pulmonary embolism, and anemia (Goldman & Ausiello 2007).  Of 
the CL patients who reported a history of tachypnea, 12/13 (92.3%) reported a diagnosis or 
history of at least one other pulmonary condition.  Therefore, it is suggested that those reporting 
a history of tachypnea may actually have an underlying condition causing the changes in 
breathing rate.   
A limitation of the clinical questionnaires and medical histories  is a lack of no 
consistency between who reports and fills out the information.  Referring physicians, patients, 
and members of our research group have reported and filled out the information.  The concern is 
the difference in level of knowledge of medical terminology, and bias in respect to what type of 
information is reported.  Also, for conditions and symptoms that are determined by quantitative 
measurements, such as tachypnea which is determined by the breathing rate per minute, these are 
not defined. 
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6.2 ONSET CLASSIFICATION & PULMONARY INVOLVEMENT 
The common pulmonary responses between the different groups of onset were similar to the 
general responses.  For congenital onset patients, pneumonia (23.1%) and tachypnea (21.2%) 
were the two most common responses.  For unknown onset patients, a history of pneumonia 
(26.1%) and emphysema (13.0%) were the two most common responses.  These answers were 
expected after determining that all three responses were the most common as a whole.  For 
acquired/late-onset patients the only responses were emphysema, pneumonia, and dyspnea.  
Even though dyspnea, shortness of breath, was determined to be statistically significant, it most 
likely is a symptom of other pulmonary conditions.  For instance, one of the patients with 
dyspnea also reported emphysema, which is a predominant reported symptom of obstructive lung 
disease.  A potential explanation includes that adults may be more likely to report symptoms like 
dyspnea than other age groups.  In general, the results for the three groups of onset demonstrate a 
clinical overlap of pulmonary involvement. 
In respect to the PFTs collected, patients either had normal lung function or obstruction.  
No patients had restrictive or mixed defects of obstructive and restrictive lung function.  Of the 4 
patients with acquired/late-onset, pulmonary function ranged from mild to very severe 
obstruction.  These 4 acquired/late-onset patients were the same 4 patients who accounted for all 
acquired/late-onset pulmonary responses on questionnaires and medical histories.  For congenital 
patients, pulmonary function ranged from normal to moderate obstruction, and the one unknown 
patient had normal function.  As described, obstructive lung disease can include diagnoses such 
as COPD, emphysema, chronic bronchitis, asthma, or bronchiectasis.  Only 2 out of 7 (28.6%) of 
the patients with obstruction found on the PFT reported a related diagnosis (emphysema and 
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asthma).   When related symptoms like dyspnea are included, then 4 out of 7 (57.1%) of the 
patients have a related diagnosis or history.   
Interestingly, 2 out of 3 congenital patients with obstruction did not note any pulmonary 
conditions or symptoms on their clinical questionnaires.  Both of these patients when evaluated 
were in late adolescence/early adulthood.  This suggests a difference in likelihood of reporting 
symptoms such as difficulty breathing or dyspnea.  One possible explanation is that 
acquired/late-onset patients are more attuned to the changes occurring due to developing 
symptoms of cutis laxa later in life.  Congenital patients may potentially be used to their health 
complications, and be unaware that things, like their ability to breath, should be different. 
6.3 CL TYPES & PULMONARY INVOLVEMENT 
Mutations were identified in 27 of the 83 patients, and in 5 carriers.  Based on the gene mutation, 
it was determined that these 27 patients represent cases of ADCL, ARCL1, ARCL2A, and 
URDS.  The absence of mutations in ATP7A, PYCR1, and RIN2 does not necessarily mean that 
none of our patients have a mutation in one of these three genes.  If available, serum copper and 
ceruloplasmin levels are recorded for patients.  This is an indirect genetic assessment for ATP7A.  
For the other genes it is most likely attributable to the fact that our laboratory currently does not 
screen patients for mutations in these genes.   
In respect to mutational status and age of onset, pulmonary complications have 
previously been described for ADCL, ARCL1, URDS, and acquired/late-onset.  This study 
confirms these findings.  However, of note, several of the patients with mutations were 
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previously described in literature.  Therefore, the reported pulmonary involvements did not 
confirm previous findings, but restated previously reported findings.  For ADCL, 3 of our 7 of 
our cases were previously described by Szabo et al. (2006) and were noted to not have any 
pulmonary involvement.  For ARCL1, both cases used were previously described by 
Hucthagowder et al. (2006) and Claus et al. (2008).  However, for URDS and acquired/late-
onset, the majority of cases described here are new cases not previously described; thus 
confirming and expanding on previous reports. 
Comparison of pulmonary responses by mutational status, thus between the CL types 
with known genetic causes, demonstrated no statistically significant associations.   This may 
suggest an overlap of pulmonary phenotype between the CL types and does not support a 
phenotype-genotype correlation for pulmonary involvement.  However, it is important to 
consider that the small sample sizes limit the ability to draw firm conclusions. 
An important finding, regardless of statistical significance, is the presence of pulmonary 
involvement in ARCL2A.  In previous reports, patients with ARCL2A were not noted to have 
any diagnosis or history of a pulmonary condition.  In our cohort, of the 5 patients with 
ARCL2A, 2 (40%) reported a history of infectious related pulmonary disease.  These included 
bronchiectasis, in which onset is typically related to a bacterial or viral infection, and pneumonia.  
As already discussed, association between respiratory infections and obstructive lung disease has 
been shown.  In addition, a third ARCL2A patient was found to have moderate obstruction on 
the PFT.  Collection of more complete pulmonary data on patients with ARCL2A is needed to 
better define the pulmonary involvement and to determine if pulmonary complications are part of 
the clinical spectrum for ARCL2A. 
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6.4 URDS (LTBP4-RELATED CL) 
Of the gene mutations identified, 48.1% (13/27) were identified to have LTBP4 mutations.  
Therefore, patients with LTBP4 mutations, or URDS, represent the largest type of CL within our 
CL cohort.  This study presents 9 new cases in which patients have at least one LTBP4 mutation; 
therefore presenting the largest group of URDS patients.  To date, only 4 patients have 
previously been reported to have LTBP4 mutations (Urban et al. 2009).  Based on the frequency 
of LTBP4 mutations within our CL cohort, it is suggestive that URDS may be the most prevalent 
type of autosomal recessive CL.  As a result, screening of LTBP4 should be considered first for 
patients with multi-systemic involvement and are suggestive of autosomal recessive inheritance. 
As noted, only one LTBP4 mutation has been identified in 6/13 of these patients.  Of the 
patients with compound heterozygous or homozygous mutations, 5/6 had at least one frame-shift 
or nonsense mutation.  For patients with only one identified mutation, 5/6 have a missense 
mutation.  There is a question as to whether patients with only one mutation have different 
phenotypic features and if the presence of a missense mutation is associated with unique 
features.  However, at this time the significance of mutation type between the two groups of 
URDS patients is unclear.  For pulmonary involvement, comparison of the responses between 
the two groups indicated no significant associations (p-values ranged from 0.3500 to 1.000). 
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6.5 HETEROZYGOUS CARRIERS OF RECESSIVE CL MUTATIONS 
Five carriers were included in this study.  All 5 individuals were first-degree relatives of patients 
and presented with no cutaneous involvement.  These individuals either had a FBLN4 mutation 
(ARCL1 carrier) or a LTBP4 mutation (URDS carrier).  Two carriers, 1 ARCL1 carrier and 1 
URDS carrier, reported a history of pneumonia.  Pneumonia is a common disease in the general 
population and consequently, the history of pneumonia is most likely an incidental finding.   One 
URDS carrier was reported to have multiple pulmonary conditions.  This carrier was the child of 
parents (the other two URDS carriers) who had previously lost a child with URDS.  Therefore, it 
is unclear whether this is a relevant association or an incidental finding.  Finally the 3 URDS 
carriers had PFTs performed, and all were found to have normal lung function.  Due to the small 
number of carriers, it is not possible to ascertain whether carriers are more likely to develop 
pulmonary disease or are more susceptible to conditions like COPD.  To better determine the risk 
for pulmonary disease, a study with a larger number of carriers who are followed over time to 
monitor their pulmonary status would be necessary. 
6.6 PUBLIC HEALTH SIGNIFICANCE: CHRONIC LUNG DISEASE 
Chronic lung disease is a common cause of morbidity in the general population. There have been 
a number of studies and reviews that have discussed genetic causes, susceptibilities, and 
associations of COPD and related conditions.  Examples include, and are not limited to, AAT, 
AACT, EPHX1, GSTs, HMOX1, TNF-alpha, CFTR, SFTPD, TGFB1, LTBP4, STAT1, NFKBIB, 
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and GC (Bakke et al. 2011, Hersh et al. 2006, Sandford & Silverman 2004).  However, the 
associations identified have not always been replicated..  Uncovering the genetic basis of chronic 
lung disease in inherited syndromes identifies key molecular targets for improved diagnosis and 
treatment of common respiratory ailments.   
The best described genetic susceptibility for chronic lung disease, specifically early-onset 
emphysema, is alpha-1 antitrypsin (AAT) deficiency.  About 1 in 3000 to 1 in 5000 are affected 
with AAT deficiency (Silverman & Sandhaus 2009).  The majority of individuals with AAT 
deficiency have a PI ZZ or PI ZNull genotype (two copies of the PI*Z allele or one copy of PI*Z 
allele and one copy of PI*Null allele).  A diagnosis is most commonly made by measurement of 
plasma AAT level and either protease inhibitor (PI) typing or detection of mutation.  The 
common clinical presentation of those with AAT deficiency is early-onset panacinar emphysema 
in adults, however individuals may present with other types of emphysema.  Other features and 
symptoms may include bronchiectasis, dyspnea, chronic cough, or wheezing (Silverman & 
Sandhaus 2009).  However, AAT deficiency only accounts for less than 1% of all emphysema 
cases (Silverman & Sandhaus 2009, Barnes 2004). 
Identifying mutations or variants in genes associated with conditions in which patients 
are known to have chronic obstructive pulmonary involvement, like CL, and determining the 
functional and physiological impact may allow for a better understanding of the causes and 
susceptibilities to COPD.  Examples of studies that found associations with CL-related genes 
include Cho et al. (2009) and Hersh et al. (2006).  Cho et al. (2009) found the elastin variant 
G773D in 1-2% of individuals in a severe COPD cohort.  However, they were unable to find 
other elastin variants that demonstrated a strong association with COPD in their cohorts.  Hersh 
et al. (2006) looked at COPD-related phenotypes and found four genes to be associated, which 
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included LTBP4.  Additional research on carriers of autosomal recessive CL types may allow for 
identification of associations of CL-related genes and chronic lung diseases. 
6.7 FUTURE DIRECTIONS 
6.7.1 Additional Pulmonary Data 
Analyzing subsets of the clinical data collected on our CL cohort allows for better 
characterization of specific systemic involvement.  In addition, it is possible to further define the 
clinical presentation of the different types of CL.  For instance, the pulmonary involvement in 
ARCL2A was identified due to comparing respiratory responses and classification of pulmonary 
function.  Continued collection of clinical data will aid this process. It will also allow for more 
statistical power, and the potential identification of genotype-phenotype correlations.  Also, it 
will be important to follow-up with patients to monitor progression of disease. 
Additional pulmonary data could be collected for individuals withARCL2A and 
heterozygous carriers for recessive types of CL.  With respect to the pulmonary complications in 
those with ARCL2A, it would be important to follow-up on the findings from this study and 
determine whether other patients have similar respiratory responses and/or lung function.  This 
could possibly involve contacting other research groups, physicians, and patients and suggesting 
that these patients have a pulmonary evaluation.  For CL heterozygous carriers, based on the data 
collected on the 3 LTBP4 and 2 FBLN4 carriers it is unclear whether the reported pulmonary 
conditions and symptoms are related to the mutational status or are incidental findings.  To 
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clarify these results clinical questionnaires and PFTs on other carriers could be collected.  To 
ascertain the risk for chronic lung diseases like COPD, follow-up could include monitoring for 
any changes in lung function. 
Finally, to account for confounders of pulmonary disease additional information should 
be considered when analyzing future pulmonary data.  Confounders include such things as 
occupational or environmental exposures, genetic susceptibilities like AAT deficiency, age, 
gender, and race/ethnicity.   For exposures, respiratory questionnaires that specifically ask about 
environmental and occupational exposure histories will be used.   In regards to AAT deficiency, 
determining a patient’s status would allow for better characterization of the impact of CL 
causative genes on the development of chronic lung disease.  Finally, consideration of such 
factors would aid in determining whether a patient’s pulmonary presentation was related solely 
to their CL, or a combination of CL and other susceptibility factors.    
6.7.2 Chest CT Collection and Analysis 
Finally, in this study to determine the type of pulmonary function, only PFTs were used.  
A benefit of PFTs is the availability of standardized protocols published by the American 
Thoracic Society (ATS) that are used by most centers to evaluate patients.  PFT parameters such 
as FEV1, FVC, and FEV1/FVC are used to determine the presence, type, and severity of disease 
affecting pulmonary function.  However, these measurements, as discussed by Han et al (2010), 
only explain a fraction (10-25%) of the impact of the disease on the patient.  Chest computed 
tomography (CT) scans have been shown to provide more specific information regarding the 
cause and progression of lung disease (Han et al. 2010, Kim et al. 2009).  Therefore, to 
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determine the cause or type of chronic lung disease, it would be valuable to collect chest CT 
scans on patients. 
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7.0  CONCLUSION 
Cutis laxa is a group of conditions characterized by the cutaneous features.  Other systemic 
involvement includes genitourinary, gastrointestinal, pulmonary, cardiovascular, and 
neurobehavioral.  This study aimed to better define the pulmonary involvement.  Through 
analysis of clinical questionnaires, medical histories, and PFTs, this study provided a qualitative 
and quantitative assessment of types of pulmonary conditions seen in CL.  In our cohort, 
emphysema and pneumonia were two of the most common responses.  Therefore, the primary 
findings confirmed previous reports indicating obstructive lung disease and recurrent respiratory 
infections as the primary pulmonary involvement.   Even though there were no significant 
differences in the type of pulmonary conditions between onset groups (acquired/late-onset, 
congenital, unknown) or types of CL based on mutational status, the information provided here 
demonstrates the heterogeneity and clinical overlap of CL.   
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APPENDIX B 
2011 CLINICAL QUESTIONNAIRE 
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CUTIS LAXA 
Patient/Physician questionnaire 
Family ID:_________________________ 
Participant ID:______________________ 
 
RACE: 
American Indian or Alaskan   [ ] 
Asian      [ ] 
Black or African American   [ ] 
Native Hawaiian or Other Pacific Islander: [ ] 
Other race (please specify): ____________________________________________ 
Two or More Races (please specify): ____________________________________ 
White:      [ ] 
ETHNICITY: 
Hispanic or Latino    [ ] 
Other ethnicity (please specify): _________________________________________ 
 
Definitions: 
American Indian or Alaska Native: A person having origins in any of the original peoples of North, Central, 
or South America, and who maintains tribal affiliation or community attachment.  
Asian: A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian 
subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine 
Islands, Thailand, and Vietnam.  
Black or African American: A person having origins in any of the black racial groups of Africa. Terms such 
as “Haitian” or “Negro” can be used in addition to “Black or African American.” 
Native Hawaiian or Other Pacific Islander: A person having origins in any of the original peoples of 
Hawaii, Guam, Samoa, or other Pacific Islands.  
White: A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.  
Hispanic or Latino: A person of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish 
culture or origin, regardless of race. The term, “Spanish origin,” can be used in addition to “Hispanic or 
Latino”. 
PAST MEDICAL HISTORY 
------------------------------------------------------------------------------------------------------------ 
Birth Data: 
Date of birth (mo/day/year):   __/__/__  Male:  [ ] Female:  [ ] 
Gestational age at birth: ______ weeks    
Birth weight: ______  Length: _______   Head circumference: _______  
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Amniotic fluid: Oligohydramnios:  [ ] Normal:  [ ]  Polyhydramnios:  [ ]  
Fetal movements: Reduced:  [ ]  Normal:  [ ]  Increased:  [ ] 
Fetal ultrasound: Normal:  [ ]  Abnormal:  [ ]  Not performed:  [ ] 
Ultrasound abnormalities      Gestational age     
 
 
 
Death Data: 
If deceased, date of death (mo/day/year): __/__/__ 
Cause of death:                                                                                
 
 
 
_____________________________________________________________________________ 
Previous Surgical History: 
 
 
 
 
History of abdominal vascular surgery: Yes  [ ]       No  [ ]       ?  [ ] 
  
History of any facial surgeries:  Yes  [ ]       No  [ ]       ?  [ ] 
If yes, type(s) of surgeries: 
 
 
Cosmetic surgeries: 
Face lift: Yes  [ ]       No  [ ]       ?  [ ] 
Date(s):______________________    
Other:________________      Date(s):______________________ 
         _________________     Date(s):______________________ 
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Previous Hospitalizations: 
 
 
 
 
History of any trauma that affected the facial structure:  Yes  [ ]       No  [ ]       ?  [ ] 
If yes, document here: 
 
 
 
 
Medications: 
 
 
 
 
Allergies: Yes  [ ]       No  [ ]       ?  [ ] 
Allergens: 
 
 
 
 
Skin affected: Yes  [ ]       No  [ ]       ?  [ ] 
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3 GENERATION PEDIGREE 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Patient:_________________________________________    Paternal Ethnicity:_________________________________ 
Historian:_______________________________________    Maternal Ethnicity:________________________________ 
Completed By:________________ Date:______________    Consanguinity:____________________________________ 
Updated By:__________________ Date:______________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Family Review of Systems (Please note findings on pedigree): 
LD/DD/MR Yes No Gastrointestinal Problems Yes No Diverticulae Yes No 
Respiratory Problems Yes No Genitourinary Problems Yes No Hernias Yes No 
Cardiovascular Problems Yes No Skeletal Problems Yes No Growth Delay Yes No 
Skin: At least 2-3 of the following  
(i) Loose, lax; (ii) Redundant; (iii) Inelastic; (iv) Premature aging of the skin; (v) Skin wrinkling 
Yes No 
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CLINICAL DESCRIPTION 
------------------------------------------------------------------------------------------------------------ 
Age at examination: ________ 
Age when symptoms began: ________ 
 
SKIN: 
Lax:  Yes  [ ]       No  [ ]       ?  [ ] 
Redundant: Yes  [ ]       No  [ ]       ?  [ ] 
Inelastic: Yes  [ ]       No  [ ]       ?  [ ] 
Loose facial skin:  Yes  [ ]       No  [ ]       ?  [ ] 
Premature aging of the skin: Yes  [ ]       No  [ ]       ?  [ ] 
Skin wrinkling:  Yes  [ ]       No  [ ]       ?  [ ] 
Affected skin:   Generalized  [ ] Localized  [ ] 
If localized:   Symmetric  [ ] Asymmetric  [ ] Flexural  [ ] Focal  [ ] 
Transparent skin:  Yes  [ ]       No  [ ]       ?  [ ] 
Inflammatory skin disease: Yes  [ ]       No  [ ]       ?  [ ] 
Other skin findings: 
 
CRANIOFACIAL: 
Facial drooping:  Yes  [ ]       No  [ ]       ?  [ ] 
Wizened appearance:  Yes  [ ]       No  [ ]       ?  [ ] 
Large fontanels:  Yes  [ ]       No  [ ]       ?  [ ] 
Delayed closure of fontanels: Yes  [ ]       No  [ ]       ?  [ ] 
Oxycephaly:   Yes  [ ]       No  [ ]       ?  [ ] 
Frontal bossing:  Yes  [ ]       No  [ ]       ?  [ ] 
Reversed-V eyebrows:  Yes  [ ]       No  [ ]       ?  [ ] 
Downward slanting palpebral fissures: Yes  [ ]       No  [ ]       ?  [ ] 
Hooked nose:   Yes  [ ]       No  [ ]       ?  [ ] 
Long philtrum:   Yes  [ ]       No  [ ]       ?  [ ] 
Occipital horns:  Yes  [ ]       No  [ ]       ?  [ ] 
Other craniofacial findings: 
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ORAL: 
Vocal cord laxity: Yes  [ ]       No  [ ]       ?  [ ] 
Hoarse voice:  Yes  [ ]       No  [ ]       ?  [ ] 
Dental caries:  Yes  [ ]       No  [ ]       ?  [ ] 
Other oral findings: 
 
EYES: 
Retinovascular tortuosity: Yes  [ ]       No  [ ]       ?  [ ] 
Corneal opacities:  Yes  [ ]       No  [ ]       ?  [ ] 
Corneal arcus:   Yes  [ ]       No  [ ]       ?  [ ] 
Cataract:   Yes  [ ]       No  [ ]       ?  [ ] 
Other eye findings: 
 
NEUROBEHAVIORAL: 
Hypotonia:   Yes  [ ]       No  [ ]       ?  [ ] 
Congenital bilateral athetosis: Yes  [ ]       No  [ ]       ?  [ ] 
Mental retardation:  Yes  [ ]       No  [ ]       ?  [ ] 
 IQ Test type:_____________  Value:________ 
Education history: 
Social history: 
Other neurobehavioral findings: 
 
RESPIRATORY: 
Bronchiectasis:   Yes  [ ]       No  [ ]       ?  [ ] 
Hypoplastic lungs (newborn): Yes  [ ]       No  [ ]       ?  [ ] 
Emphysema:   Yes  [ ]       No  [ ]       ?  [ ] 
Tachypnea:   Yes  [ ]       No  [ ]       ?  [ ] 
Pneumonia:   Yes  [ ]       No  [ ]       ?  [ ] 
Asthma:   Yes  [ ]       No  [ ]       ?  [ ] 
Chest CT findings and date: ___________________________________________ 
Pulmonary function test (PFT) findings and date:  ___________________________ 
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Current smoker:  Yes  [ ]       No  [ ]        
Cigarette packs per day: ___________________________ 
Years smoked:   ___________________________ 
Other respiratory findings: 
 
CARDIOVASCULAR: 
Cor pulmonale:    Yes  [ ]       No  [ ]       ?  [ ] 
Right ventricular hypertrophy:  Yes  [ ]       No  [ ]       ?  [ ] 
Infundibular stenosis:  Yes  [ ]       No  [ ]       ?  [ ] 
Pulmonary valve stenosis: Yes  [ ]       No  [ ]       ?  [ ] 
Pulmonary artery stenosis: Yes  [ ]       No  [ ]       ?  [ ] 
 Murmur (6 scale):________________ 
 Pressure gradient (Hgmm):________________ 
 Peak velocity (m/s):____________________ 
Peripheral pulmonary stenosis: Yes  [ ]       No  [ ]       ?  [ ] 
Aortic stenosis:  Yes  [ ]       No  [ ]       ?  [ ] 
Murmur (6 scale):________________ 
 Pressure gradient (Hgmm):________________ 
 Peak velocity (m/s):____________________ 
Aortic dilatation:  Yes  [ ]       No  [ ]       ?  [ ] 
 Level:____________ 
 Diameter:__________ 
Arterial tortuosity:  Yes  [ ]       No  [ ]       ?  [ ] 
 Which arteries:____________________________ 
Arterial aneurysms:  Yes  [ ]       No  [ ]       ?  [ ] 
 Which arteries:____________________________ 
Raynaud’s phenomenon: Yes  [ ]       No  [ ]       ?  [ ] 
Venous varicosity:  Yes  [ ]       No  [ ]       ?  [ ] 
Echocardiogram (Echo) findings and date:__________________________________ 
Other cardiovascular findings: 
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GASTROINTESTINAL: 
Diverticulae: Esophageal: Yes  [ ]       No  [ ]       ?  [ ] 
  Duodenal: Yes  [ ]       No  [ ]       ?  [ ] 
  Rectal:  Yes  [ ]       No  [ ]       ?  [ ] 
  Other:_____________________________ 
Other gastrointestinal findings: 
 
GENITOURINARY: 
Bladder diverticulae:  Yes  [ ]       No  [ ]       ?  [ ] 
Genital prolapse:  Yes  [ ]       No  [ ]       ?  [ ] 
Obstructive uropathy:  Yes  [ ]       No  [ ]       ?  [ ] 
Bladder neck obstruction: Yes  [ ]       No  [ ]       ?  [ ] 
Other genitourinary findings: 
 
MUSCULOSKELETAL: 
Hernias: Inguinal:  Yes  [ ]       No  [ ]       ?  [ ] 
  Diaphragmatic: Yes  [ ]       No  [ ]       ?  [ ] 
Hiatal:   Yes  [ ]      No  [ ]       ?  [ ] 
Umbilical:  Yes  [ ]       No  [ ]       ?  [ ] 
Hip dislocation:   Yes  [ ]       No  [ ]       ?  [ ] 
Thumbs and/or toes dislocated: Yes  [ ]       No  [ ]       ?  [ ] 
Joint laxity:  Yes  [ ]       No  [ ]       ?  [ ] 
Pectus carinatum: Yes  [ ]       No  [ ]       ?  [ ] 
Pectus excavatum: Yes  [ ]       No  [ ]       ?  [ ] 
Scoliosis:  Yes  [ ]       No  [ ]       ?  [ ] 
Flat feet:  Yes  [ ]       No  [ ]       ?  [ ] 
Short broad clavicles: Yes  [ ]       No  [ ]       ?  [ ] 
Fused carpal bones: Yes  [ ]       No  [ ]       ?  [ ] 
Other musculoskeletal findings: 
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GROWTH: 
Growth deficiency/delay: 
 Prenatal: Yes  [ ]       No  [ ]       ?  [ ] 
 Postnatal Yes  [ ]       No  [ ]       ?  [ ] 
 Dwarfism Yes  [ ]       No  [ ]       ?  [ ] 
Physical data: 
Age   Weight   Height                  Head circumference    
                          
                                                                                                                                               
 
 
OTHER ABNORMALITIES NOT LISTED ABOVE:      
             
             
              
 
LABORATORY: 
Reduced elastin synthesis:  Yes  [ ]       No  [ ]       ?  [ ] 
Abnormal elastic fibers: 
  Histology:  Yes  [ ]       No  [ ]       ?  [ ] 
  EM:   Yes  [ ]       No  [ ]       ?  [ ] 
Reduced lysyl oxidase activity: Yes  [ ]       No  [ ]       ?  [ ] 
Serum ceruloplasmin:_____________________________ 
Serum copper:___________________________________ 
 
ADDITIONAL INFORMATION: 
Clinical photographs available: Yes  [ ]       No  [ ] 
DNA available:   Yes  [ ]       No  [ ] 
Cultured cells available:  Yes  [ ]       No  [ ] 
Pathology slides available:  Yes  [ ]       No  [ ] 
Frozen tissue available:  Yes  [ ]       No  [ ] 
Patient available for re-examination: Yes  [ ]       No  [ ] 
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CUTIS LAXA 
Contact Information 
 
PARTICIPANT  
 
Family ID: _________________________ 
Participant ID:______________________ 
 
Participant’s Name:________________________________________________________ 
Parent’s or Guardian’s Name (if participant is minor):_____________________________ 
Address:_______________________________________________ 
______________________________________________________ 
______________________________________________________ 
Phone:_____________________________ 
Fax:_______________________________ 
Email:______________________________ 
 
 
REFERRING PHYSICIAN 
 
Physician’s Name:________________________________________ 
Address:________________________________________________ 
_______________________________________________________ 
_______________________________________________________ 
Phone:_____________________________ 
Fax:_______________________________ 
Email:______________________________ 
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APPENDIX C 
PFT REFERENCE VALUES
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Table 9: Prediction and Lower Limit of Normal Equations for Spirometric Parameters for Male Subjects 
Male Subjects  Intercept (b0) Age (b1) Age^2 (b2) Ht LLN (cm)^2 (b3) 
Caucasian < 20 yr of age FEV1 -0.7453 -0.04106 0.004477 0.00011607 
 FEV6 -0.3119 -0.18612 0.009717 0.00015323 
 FVC -0.2584 -0.20415 0.010133 0.00015695 
 PEF -0.5962 -0.12357 0.013135 0.00017635 
 FEF 25-75 -1.0863 0.13939 0 0.00005294 
Caucasian ≥ 20 yr of age FEV1 0.5536 -0.01303 -0.000172 0.00011607 
 FEV6 0.1102 -0.00842 -0.000223 0.00015323 
 FVC -0.1933 0.00064 -0.000269 0.00015695 
 PEF 1.0523 0.08272 -0.001301 0.00017635 
 FEF 25-75 2.7006 -0.04995 0 0.00005294 
African-American < 20 yr of age FEV1 -0.7048 -0.05711 0.004316 0.00010561 
 FEV6 -0.5525 -0.14107 0.007241 0.00013499 
 FVC -0.4971 -0.15497 0.007701 0.0001367 
 PEF -0.2684 -0.28016 0.018202 0.00018938 
 FEF 25-75 -1.1627 0.12314 0 0.00004819 
 
 
86 
 
Table 9 (Continued). 
African-American ≥ 20 yr of age FEV1 0.3411 -0.02309 0 0.00010561 
 FEV6 -0.0547 -0.02114 0 0.00013499 
 FVC -0.1517 -0.01821 0 0.0001367 
 PEF 2.2257 -0.04982 0 0.00018938 
 FEF 25-75 2.1477 -0.04238 0 0.00004819 
Mexican-American < 20 yr of age FEV1 -0.8218 -0.04248 0.004291 0.0001267 
 FEV6 -0.6646 -0.1127 0.007306 0.00015029 
 FVC -0.7571 -0.0952 0.006619 0.00014947 
 PEF -0.9537 -0.19602 0.014497 0.00021833 
 FEF 25-75 -1.3592 0.10529 0 0.0000902 
Mexican-American ≥ 20 yr of age FEV1 0.6306 -0.02928 0 0.0001267 
 FEV6 0.5757 -0.0286 0 0.00015029 
 FVC 0.2376 -0.00891 -0.000182 0.00014947 
 PEF 0.087 0.0658 -0.001195 0.00021833 
 FEF 25-75 1.7503 -0.05018 0 0.0000902 
 
Table is adapted from Hankinson, Odencrantz, & Fedan (1999). 
The equation used to determine the lung function parameter is: LLN = b0 + b1 * age + b2 * age2 + b3 * height2.
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Table 10: Prediction and Lower Limit of Normal Equations for Spirometric Parameters for Female Subjects 
Female Subjects  Intercept (b0) Age (b1) Age^2 (b2) Ht LLN (cm)^2 (b3) 
Caucasian < 18 yr of age FEV1 -0.871 0.06537 0 0.00009283 
 FEV6 -1.1925 0.06544 0 0.00011827 
 FVC -1.2082 0.05916 0 0.00012198 
 PEF -3.6181 0.60644 -0.016846 0.00012148 
 FEF 25-75 -2.5284 0.5249 -0.015309 0.00002302 
Caucasian ≥ 18 yr of age FEV1 0.4333 -0.00361 -0.000194 0.00009283 
 FEV6 -0.1373 0.01317 -0.000352 0.00011827 
 FVC -0.356 0.0187 -0.000382 0.00012198 
 PEF 0.9267 0.06929 -0.001031 0.00012148 
 FEF 25-75 2.367 -0.01904 -0.0002 0.00002302 
African-American < 18 yr of age FEV1 -0.963 0.05799 0 0.00008546 
 FEV6 -0.637 -0.04243 0.003508 0.00010848 
 FVC 0.6166 -0.04687 0.003602 0.00010916 
 PEF -1.2398 0.16375 0 0.0001216 
 FEF 25-75 -2.5379 0.43755 -0.012154 0.0000338 
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Table 10 (Continued). 
African-American ≥ 18 yr of age FEV1 0.3433 -0.01283 -0.000097 0.00008546 
 FEV6 -0.1981 0.00047 -0.00023 0.00010848 
 FVC -0.3039 0.00536 -0.000265 0.00010916 
 PEF 1.3597 0.03458 -0.000847 0.0001216 
 FEF 25-75 2.0828 -0.03793 0 0.0000338 
Mexican-American < 18 yr of age FEV1 -0.9641 0.0649 0 0.0000989 
 FEV6 -1.241 0.07625 0 0.0001148 
 FVC -1.2507 0.07501 0 0.0001157 
 PEF -3.2549 0.47495 -0.013193 0.00014611 
 FEF 25-75 -2.1825 0.42451 -0.012415 0.00004594 
Mexican-American ≥ 18 yr of age FEV1 0.4529 -0.01178 -0.000113 0.0000989 
 FEV6 0.2033 0.0002 -0.000232 0.0001148 
 FVC 0.121 0.00307 -0.000237 0.0001157 
 PEF 0.2401 0.06174 -0.001023 0.00014611 
 FEF 25-75 1.7456 -0.01195 -0.000291 0.00004594 
 
Table is adapted from Hankinson, Odencrantz, & Fedan (1999). 
The equation used to determine the lung function parameter is: LLN = b0 + b1 * age + b2 * age2 + b3 * height2. 
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Table 11: Prediction and Lower Limit of Normal Equations for FEV1/FEV6% and FEV1/FVC% for Male and Female Subjects 
Male Subjects  Intercept LLN (b0) Age (b1) 
Caucasian  FEV1/FEV6% 78.372 -0.1382 
 FEV1/FVC% 78.388 -0.2066 
African-American FEV1/FEV6% 78.979 -0.1305 
 FEV1/FVC% 78.822 -0.1828 
Mexican-American FEV1/FEV6% 80.81 -0.1534 
 FEV1/FVC% 80.925 -0.2186 
Female Subjects    
Caucasian  FEV1/FEV6% 81.307 -0.1563 
 FEV1/FVC% 81.015 -0.2125 
African-American FEV1/FEV6% 81.396 -0.1558 
 FEV1/FVC% 80.978 -0.2039 
Mexican-American FEV1/FEV6% 83.034 -0.167 
 FEV1/FVC% 83.044 -0.2248 
 
Table is adapted from Hankinson, Odencrantz, & Fedan (1999). 
The equation used to determine the lung function parameter is: LLN = b0 + b1 * age.
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Table 12: CL Patient Reference Values for FEV1. 
Family ID Patient ID Gender Race Age Height Intercept 
(b0) 
Age  
(b1) 
Age^2  
(b2) 
Ht LLN (cm)^2  
(b3) 
LLN FEV1 
Reference Value 
CL-04 7166 Female Hispanic 34 157.48 0.4529 -0.01178 -0.000113 0.0000989 2.374467095 
CL-15 7006 Female Caucasian 45 171 0.4333 -0.00361 -0.000194 0.00009283 2.59244203 
CL-15 7007 Male Caucasian 43 175 0.5536 -0.01303 -0.000172 0.00011607 3.22992575 
CL-15 7192 Male Caucasian 8 129.54 -0.7453 -0.04106 0.004477 0.00011607 1.160473588 
CL-16 7009 Male Caucasian/Asian 11 158 -0.7453 -0.04106 0.004477 0.00011607 2.24232848 
CL-50 7065 Female Caucasian 58 160 0.4333 -0.00361 -0.000194 0.00009283 1.947752 
CL-50 7065 Female Caucasian 63 161.29 0.4333 -0.00361 -0.000194 0.00009283 1.850806702 
CL-50 7065 Female Caucasian 65 161.29 0.4333 -0.00361 -0.000194 0.00009283 1.793922702 
CL-65 7093 Female Caucasian 20 167.64 0.4333 -0.00361 -0.000194 0.00009283 2.892317234 
CL-94 7159 Female Caucasian 43 160.02 0.4333 -0.00361 -0.000194 0.00009283 2.296406149 
CL-94 7160 Male Caucasian 16 165.1 -0.7453 -0.04106 0.004477 0.00011607 2.907689221 
CL-95 7161 Male Caucasian 40 172.72 0.5536 -0.01303 -0.000172 0.00011607 3.219823268 
CL-96 7162 Female Caucasian 39 173.99 0.4333 -0.00361 -0.000194 0.00009283 2.807634041 
CL-115 7197 Female Caucasian 64 160 0.4333 -0.00361 -0.000194 0.00009283 1.784084 
CL-116 7198 Male Black /  
African American 
(Bahamian) 
40 181.5 0.3411 -0.02309 0 0.00010561 2.896531023 
CL-117 7202 Male African American / 
American Indian 
11 149 -0.7048 -0.05711 0.004316 0.00010561 1.53387361  
See Table 1 & Table 2 for reference values and the equation used to determine the lower limit of normal (LLN) for FEV1. 
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Table 13: CL Patient Reference Values for FVC. 
Family ID Patient ID Gender Race Age Height Intercept 
(b0) 
Age (b1) Age^2 
(b2) 
Ht LLN (cm)^2 
 (b3) 
LLN FVC 
Reference Value 
CL-04 7166 Female Hispanic 34 157.48 0.121 0.00307 -0.000237 0.0001157 2.820762261 
CL-15 7006 Female Caucasian 45 171 -0.356 0.0187 -0.000382 0.00012198 3.27876718 
CL-15 7007 Male Caucasian 43 175 -0.1933 0.00064 -0.000269 0.00015695 4.14343275 
CL-15 7192 Male Caucasian 8 129.54 -0.2584 -0.20415 0.010133 0.00015695 1.390628991 
CL-16 7009 Male Caucasian/Asian 11 158 -0.2584 -0.20415 0.010133 0.00015695 2.6401428 
CL-50 7065 Female Caucasian 58 160 -0.356 0.0187 -0.000382 0.00012198 2.56624 
CL-50 7065 Female Caucasian 63 161.29 -0.356 0.0187 -0.000382 0.00012198 2.479186331 
CL-50 7065 Female Caucasian 65 161.29 -0.356 0.0187 -0.000382 0.00012198 2.418794331 
CL-65 7093 Female Caucasian 20 167.64 -0.356 0.0187 -0.000382 0.00012198 3.293224628 
CL-94 7159 Female Caucasian 43 160.02 -0.356 0.0187 -0.000382 0.00012198 2.865250721 
CL-94 7160 Male Caucasian 16 165.1 -0.2584 -0.20415 0.010133 0.00015695 3.34739267 
CL-95 7161 Male Caucasian 40 172.72 -0.1933 0.00064 -0.000269 0.00015695 4.084063539 
CL-96 7162 Female Caucasian 39 173.99 -0.356 0.0187 -0.000382 0.00012198 3.484920002 
CL-115 7197 Female Caucasian 64 160 -0.356 0.0187 -0.000382 0.00012198 2.398816 
CL-116 7198 Male Black /  
African American 
(Bahamian) 
40 181.5 -0.1517 -0.01821 0 0.0001367 3.623105575 
CL-117 7202 Male African American / 
American Indian 
11 149 -0.4971 -0.15497 0.007701 0.0001367 1.7649277 
 
See Table 1 & Table 2 for reference values and the equation used to determine the lower limit of normal (LLN) for FVC. 
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Table 14:  CL Patient Reference Values for FEV1/FVC% 
Family ID Patient ID Gender Race Age Height Intercept LLN 
(b0) 
Age  
(b1) 
LLN FEV1/FVC 
Reference Value 
CL-04 7166 Female Hispanic 34 157.48 83.044 -0.2248 75.4008 
CL-15 7006 Female Caucasian 45 171 81.015 -0.2125 71.4525 
CL-15 7007 Male Caucasian 43 175 78.388 -0.2066 69.5042 
CL-15 7192 Male Caucasian 8 129.54 78.388 -0.2066 76.7352 
CL-16 7009 Male Caucasian/Asian 11 158 78.388 -0.2066 76.1154 
CL-50 7065 Female Caucasian 58 160 81.015 -0.2125 68.69 
CL-50 7065 Female Caucasian 63 161.29 81.015 -0.2125 67.6275 
CL-50 7065 Female Caucasian 65 161.29 81.015 -0.2125 67.2025 
CL-65 7093 Female Caucasian 20 167.64 81.015 -0.2125 76.765 
CL-94 7159 Female Caucasian 43 160.02 81.015 -0.2125 71.8775 
CL-94 7160 Male Caucasian 16 165.1 78.388 -0.2066 75.0824 
CL-95 7161 Male Caucasian 40 172.72 78.388 -0.2066 70.124 
CL-96 7162 Female Caucasian 39 173.99 81.015 -0.2125 72.7275 
CL-115 7197 Female Caucasian 64 160 81.015 -0.2125 67.415 
CL-116 7198 Male Black /  
African American 
(Bahamian) 
40 181.5 78.822 -0.1828 71.51 
CL-117 7202 Male African American / 
American Indian 
11 149 78.822 -0.1828 76.8112 
 
See Table 3 for reference values and the equation used to determine the lower limit of normal (LLN) for FEV1/FVC%. 
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Table 15: CL Patient Reference Values for TLC. 
Family ID Patient ID Gender Race Age Reference table Height 
(cm) 
Height 
(m) 
Reference 
value 
(Caucasian) 
Reference 
 value 
(African American) 
LLN TLC 
Reference 
Value 
CL-04 7166 Female Hispanic 34 Adult 157.48 1.5748 4.60368  3.61368 
CL-15 7006 Female Caucasian 45 Adult 171 1.71 5.496  4.506 
CL-15 7007 Male Caucasian 43 Adult 175 1.75 6.9025  5.7525 
CL-15 7192 Male Caucasian 8 Child/Adolescent 129.54 1.2954 < 90  < 90 
CL-16 7009 Male Caucasian/Asian 11 Child/Adolescent 158 1.58 < 90  < 90 
CL-50 7065 Female Caucasian 58 Adult 160 1.6 4.77  3.78 
CL-50 7065 Female Caucasian 63 Adult 161.29 1.6129 4.85514  3.86514 
CL-50 7065 Female Caucasian 65 Adult 161.29 1.6129 4.85514  3.86514 
CL-65 7093 Female Caucasian 20 Adult 167.64 1.6764 5.27424  4.28424 
CL-94 7159 Female Caucasian 43 Adult 160.02 1.6002 4.77132  3.78132 
CL-94 7160 Male Caucasian 16 Child/Adolescent 165.1 1.651 < 90  < 90 
CL-95 7161 Male Caucasian 40 Adult 172.72 1.7272 6.720328  5.570328 
CL-96 7162 Female Caucasian 39 Adult 173.99 1.7399 5.69334  4.70334 
CL-115 7197 Female Caucasian 64 Adult 160 1.6 4.77  3.78 
CL-116 7198 Male Black /  
African American 
(Bahamian) 
40 Adult 181.5 1.815 7.42185 6.531228 5.381228 
CL-117 7202 Male African American / 
American Indian 
11 Child/Adolescent 149 1.49 < 90 79.2 < 79.2 
 
References values for lung volumes are determined from Stocks & Quanjer (1995). 
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APPENDIX D 
SUPPLEMENTAL RESULTS 
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Table 16: Clinical Questionnaire Responses. 
Family ID Patient ID 
Onset 
Classification 
Bronchiectasis 
Hypoplastic 
lungs 
(newborns) 
Emphysema Tachypnea Pneumonia Asthma 
Obstructive 
sleep apnea 
Respiratory 
distress 
Bronchitis Dyspnea 
CL-023 7026 
Acquired/ 
Late-onset 
No No No No No No No No No No 
CL-050 7065 
Acquired/ 
Late-onset 
No No Yes No No No No No No Yes 
CL-068 7099 
Acquired/ 
Late-onset 
No No No No No No No No No No 
CL-088 7149 
Acquired/ 
Late-onset 
No No No No No No No No No No 
CL-096 7162 
Acquired/ 
Late-onset 
No No No No Yes No No No No No 
CL-109 7183 
Acquired/ 
Late-onset 
No No No No No No No No No No 
CL-115 7197 
Acquired/ 
Late-onset 
No No No No Yes No No No No Yes 
CL-116 7198 
Acquired/ 
Late-onset 
No No No No No No No No No Yes 
CL-015 7006 Carrier No No No No Yes No No No Yes No 
CL-015 7007 Carrier No No No No No No No No No No 
CL-015 7192 Carrier No No No Yes Yes Yes Yes No No No 
CL-044 7082 Carrier No No No No No No No No No No 
CL-044 7083 Carrier No No No No Yes No No No No No 
CL-013 7002 Congenital No No No No No No No No No No 
CL-015 7005 Congenital No No Yes Yes Yes No Yes Yes No No 
CL-016 7009 Congenital No No No No No No No No No No 
CL-016 7010 Congenital No No No No No No No No No No 
CL-018 7015 Congenital No No No No No No Yes No No No 
CL-025 7028 Congenital No Yes No Yes No No No No No No 
CL-026 7031 Congenital No No No No Yes No Yes No No No 
CL-027 7032 Congenital No No No No Yes No No No No No 
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Table 16 (Continued). 
CL-027 7033 Congenital No No No No No No No No No No 
CL-028 7034 Congenital No No No No Yes No No No No No 
CL-036 7044 Congenital No No No No No No No No No No 
CL-037 7045 Congenital No No No No No No No No No No 
CL-038 7046 Congenital No No No No No No No No No No 
CL-039 7047 Congenital Yes No No No No No No No No No 
CL-041 7051 Congenital No No No No Yes Yes No No No No 
CL-041 7052 Congenital No No No No No No No No No No 
CL-042 7053 Congenital No No No No No No No No No No 
CL-043 7054 Congenital No No No No No No No No No No 
CL-044 7055 Congenital No No Yes No No No No No No No 
CL-045 7056 Congenital Yes No No Yes No No No No No No 
CL-049 7064 Congenital No No No Yes No No No No No No 
CL-051 7066 Congenital No No No No No No No No No No 
CL-052 7067 Congenital No Yes No Yes No No No No No No 
CL-053 7069 Congenital No No No Yes No No No Yes No No 
CL-054 7070 Congenital Yes No Yes Yes Yes No No No Yes Yes 
CL-055 7071 Congenital No No No No No No No No No No 
CL-056 7072 Congenital No No No No No No No No No No 
CL-059 7077 Congenital No No No No No No No No No No 
CL-060 7078 Congenital No No Yes No No No No No No No 
CL-061 7079 Congenital No No No No No No No No No No 
CL-062 7081 Congenital No No No No No No No No No No 
CL-062 7085 Congenital No No No No No No No No No No 
CL-063 7086 Congenital No No No No No No No Yes No No 
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Table 16 (Continued). 
CL-065 7093 Congenital No No No No No No No No No No 
CL-067 7105 Congenital No No No Yes Yes No No No No No 
CL-071 7102 Congenital No No No No Yes No No No No No 
CL-072 7106 Congenital No No No Yes Yes No No No No No 
CL-073 7112 Congenital No No Yes Yes No No No No No No 
CL-075 7117 Congenital No No No No No No No No No No 
CL-076 7118 Congenital No No No No No No No No No No 
CL-078 7122 Congenital No No No No Yes No No No No No 
CL-082 7132 Congenital No No No No No No No No Yes No 
CL-086 7140 Congenital No No No No Yes No No No No No 
CL-090 7153 Congenital No No No No No Yes No No No No 
CL-094 7159 Congenital No No No No No No No No No No 
CL-094 7160 Congenital No No No Yes Yes Yes No No No No 
CL-098 7164 Congenital No No Yes No No No No No No No 
CL-100 7167 Congenital No No No No No No No No No No 
CL-102 7171 Congenital No No No No No No No No No No 
CL-105 7178 Congenital No No No No No No No No No No 
CL-113 7193 Congenital No No No No No No No No No No 
CL-117 7202 Congenital No No No No No Yes No No No No 
CL-004 7166 Unknown No No No No No Yes No No No No 
CL-011 1391707 Unknown No No No No No No No No No No 
CL-012 7001 Unknown No No No No No No No No No No 
CL-012 7008 Unknown No No No No Yes No No No No No 
CL-012 7013 Unknown No No Yes Yes Yes No Yes No No No 
CL-012 7018 Unknown No No No No Yes No No No No No 
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Table 16 (Continued). 
CL-012 7019 Unknown No No No No Yes No No No No No 
CL-017 7014 Unknown No No No No No No No No No No 
CL-046 7059 Unknown No No No No No No No No No No 
CL-047 7060 Unknown No No No No No Yes No No No No 
CL-048 7061 Unknown No No No No No No No No No No 
CL-057 7073 Unknown No No No No No No No No No No 
CL-058 7074 Unknown No No No No No No No No No No 
CL-064 7092 Unknown No No No No No No No No No No 
CL-066 7094 Unknown No No No No No No No No No No 
CL-074 7116 Unknown No No No No No No No No No No 
CL-077 7121 Unknown No No Yes No No No No No No No 
CL-087 7141 Unknown No Yes No No No No No No No No 
CL-089 7152 Unknown No No No No No No No No No No 
CL-099 7165 Unknown No No No No No No No No No No 
CL-101 7170 Unknown No No Yes Yes Yes No No No Yes No 
CL-103 7173 Unknown No No No No Yes No No No No No 
CL-104 7175 Unknown No No No No No No No No No No 
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Table 17: Pulmonary Responses by Cutis Laxa Type (No Carriers) (N = 27).* 
 
Pulmonary 
Condition 
 
Response 
Cutis Laxa Type & Gene 
 
p-value 
ADCL (%)** ARCL1 (%)** ARCL2A (%)** URDS (%)** 
ELN FBLN4 / FBLN5 ATP6V0A2 LTBP4 
Bronchiectasis Yes 0 0 1 (20.0) 2 (15.4) 0.6578 
No 7 2 4 11   
Hypoplastic lung Yes 0 0 0 2 (15.4) 0.7407 
No 7 2 5 11   
Emphysema Yes 0 1 (50.0) 0 0 0.1822 
No 7 1 5 13   
Tachypnea Yes 1 (14.3) 0 0 7 (53.9) 0.0756 
No 6 2 5 6   
Pneumonia Yes 2 (28.6) 0 1 (20.0) 4 (30.8) 1.000 
No 5 2 4 9   
Asthma Yes 2 (28.6) 0 0 1 (7.69) 0.4267 
No 5 2 5 12   
Obstructive Apnea Yes 0 0 0 1 (7.69) 1.000 
No 7 2 5 12   
Respiratory Distress Yes 0 0 0 1 (7.69) 1.000 
No 7 2 5 12   
Bronchitis Yes 0 0 0 1 (7.69) 1.000 
No 7 2 5 12   
Dyspnea Yes 0 0 0 1 (7.69) 1.000 
No 7 2 5 12   
* This table only includes affected individuals (patients), thus does not include carriers. 
**Percentages represent the percent of patients within the type of onset who responded "Yes" to the type of pulmonary condition.
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Table 18: PFT Results (FEV1, FVC, FEV1/FVC, & TLC). 
Family ID Patient ID 
Onset 
Classification 
Gene 
PFT 
Parameters 
Pre-bronchodilator Post-bronchodilator 
Actual Predicted %Predicted Actual %Predicted % Change 
CL-50 7065 
Acquired/ 
Late-onset 
  
FVC (L) 2.24 3.09 72       
FEV1 (L) 1.84 2.36 78       
FEV1/FVC (%) 82 77         
TLC (L) 3.87 4.96 78       
CL-96 7162 
Acquired/ 
Late-onset 
  
FVC (L) 4.1 3.87 106 4.32 112 6 
FEV1 (L) 2.82 3.21 88 2.97 92 4 
FEV1/FVC (%) 69 83 83 69 83 0 
TLC (Pleth) (L) 6.77 5.73 118       
CL-115 7197 
Acquired/ 
Late-onset 
  
FVC (L) 1.71 3.07 56 2 65 17 
FEV1 (L) 1.03 2.35 44 1.36 58 32 
FEV1/FVC (%) 60 77 80 68     
TLC (L)   4.9   4.46 91   
CL-116 7198 
Acquired/ 
Late-onset 
  
FVC (L) 2.4 5.6 43 3.06 55 27 
FEV1 (L) 1.14 4.45 26 1.39 31 21 
FEV1/FVC (%) 48 81 59 45 56 -4 
TLC (L)   7.26   8.42 116   
CL-16 7009 Congenital ELN 
FVC 3.54 3.4 104       
FEV1 2.74 2.83 97       
FEV1/FVC (%) 77 83 93       
TLC 5.06 4.45 113.6       
CL-65 7093 Congenital ATP6V0A2 
FVC (L) 3.98 3.91 102 4.11 105 3 
FEV1 (L) 2.22 3.36 66 2.65 79 20 
FEV1/FVC (%) 56 86 65 65 75 16 
TLC (Pleth) (L) 5.39 5.35 101       
CL-94 7159 Congenital ELN 
FVC (L) 2.27 3.18 71 2.17 68 -3 
FEV1 (L) 1.59 2.67 60 1.66 62 2 
FEV1/FVC (%) 70 84 83 77 91 12 
TLC (Pleth) (L) 4.43 4.9 90       
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Table 18 (Continued). 
CL-94 7160 Congenital ELN 
FVC (L) 4.96 4.04 123 4.93 122 -1 
FEV1 (L) 2.72 3.47 78 3.02 87 11 
FEV1/FVC (%) 55 85 64 61 72 12 
TLC (Pleth) (L) 6.67 5.13 130       
CL-117 7202 Congenital   
FVC (L) 2.69 3.07 88       
FEV1 (L) 2.17 2.81 77       
FEV1/FVC (%) 81 86 94       
TLC (L) 4.13 3.94 105       
CL-04 7166 Unknown   
FVC (L) 3.14 2.74 115 3.21 117 2 
FEV1 (L) 2.73 2.35 116 2.78 118 2 
FEV1/FVC (%) 87 86 101 87 101 0 
TLC (Pleth) (L) 4.25 4.04 105       
CL-15 7006 Carrier LTBP4 
FVC (L) 3.53 4.04 87 3.55 88 1 
FEV1 (L) 2.73 3.24 80 2.89 89 6 
FEV1/FVC (%) 77 81 95 81 81 5 
TLC (L)   5.55   5.11 92   
CL-15 7007 Carrier LTBP4 
FVC (L) 6.14 5.05 122 6.21 123 1 
FEV1 (L) 5.06 3.99 127 5.26 132 4 
FEV1/FVC (%) 82 81 101 85 105 4 
TLC (L)   6.72   7.93 118   
CL-15 7192 Carrier LTBP4 
FVC (L) 1.91 2 96       
FEV1 (L) 1.88 1.8 104       
FEV1/FVC (%) 86           
TLC (L) 2.37 2.59 92       
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